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ABSTRACT 
Objective: 
To investigate the role of hybrid 18F-FDG PET/CT as a potential risk-stratification tool 
of aneurysm expansion by measuring metabolic activity on PET and textural analysis on 
CT in abdominal aortic aneurysm (AAA). Histological markers of AAA wall 
inflammatory cell infiltrate and enzymatic degradation have been associated with 
increased 18F-Fluorodeoxyglucose (18F-FDG)-Positron Emission Tomography 
/Computed Tomography (PET/CT) uptake.    
 
Methods: 
Fifty patients with asymptomatic infrarenal AAA enrolled under surveillance at one of 
our institutions underwent 18F-FDG-PET/CT. Seventeen subjects were investigated for 
increased glucolysis in the AAA wall and optimal circulation imaging time for 18F-
FDG. In 25 subjects the relationship between aneurysm metabolic activity and 
expansion was explored. Forty subjects had AAA CT textural analysis (CTTA) 
parameters performed on the CT component of PET/CT and were studied in relation to 
aneurysm expansion. Twenty-four subjects had circulating biomarkers analysed. Whole 
vessel assessment, region of interest analysis and the role of correcting for background 
blood pool activity were explored.  
 
Results: 
Thirteen of seventeen subjects investigated for increased 18F-FDG uptake had an AAA 
wall SUVmax > 2.5. In 17 subjects assessed for optimal circulation imaging time for 
18F-FDG, no significant advantage in imaging at 3h over 1h after 18F-FDG injection was 
observed. 18F-FDG uptake correlated inversely with future AAA expansion in the 
preliminary group of 25 patients and in 40 subjects who also had CTTA. In subjects 
who had CTTA, coarse texture showed an inverse association with 18F-FDG uptake and 
medium coarse texture correlated with future AAA expansion. In 24 AAA patients who 
had serum biomarker assays, significantly higher levels of high sensitivity matrix 
metalloproteinase-9 (hsMMP-9) and hsMMP-2 compared to healthy controls were 
found. There was no correlation between AAA 18F-FDG uptake and levels of hsMMP-
9, hsMMP-2, hs-interferon-γ and hs-C-reactive protein.  
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Conclusions: 
In-vivo 18F-FDG PET/CT data indicated that small AAA show increased glucose 
metabolism. Relationships between AAA 18F-FDG uptake, CTTA and future expansion 
were identified. AAA18F-FDG PET/CT shows potential to identify subjects at risk of 
significant expansion. AAA metabolism may not relate to serum levels of certain 
inflammatory biomarkers. 
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THE AIMS OF THE THESIS 
 
The pathobiology of aortic aneurysm is both complex and multifactorial with 
inflammation suggested as a major central factor in AAA formation and progression. 
FDG PET/CT of metabolic activitity currently represents a promising imaging modality 
for detecting vascular metabolic activity. However the optimum tracer and technique of 
PET/CT and its clinical role remains to be established.  
 
The primary aim of the thesis was to explore the role of hybrid PET/CT in imaging 
AAA metabolic activity. The secondary aims were to investigate the relationships 
between aneurysmal wall tracer uptake and textural analysis of CT, serum biomarkers 
of inflammation and aneurysm growth rate.   
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  Chapter 1 Aortic aneurysm pathogenesis 
SECTION I INTRODUCTION 
CHAPTER 1. AORTIC ANEURYSM PATHOGENESIS 
 
Technological advances in molecular imaging have increased the possibilities for 
enhancing our understanding of the pathogenesis of abdominal aortic aneurysms 
(AAAs). AAA continues to pose a substantial health and economic burden, and is 
present in up to 10% of men between the ages of 65 and 79 years1. Aneurysm rupture is 
associated with 80% mortality for patients reaching emergency hospital services and 
50% for those deemed fit for emergency repair1.  Mortality rates for patients with 
ruptured aneurysms undergoing repair have remained unchanged for more than a 
decade2. The current recommendation is for aneurysms larger than 5.5 cm to have 
elective intervention to prevent rupture1.  
 
Aortic aneurysm (AA) is defined as a localized dilation of the aorta greater than 50 % of 
its diameter, involving all the layers of the vessel wall3 or maximum external diameter 
of > 3cm4. Most AAAs are asymptomatic (although back pain and tenderness over the 
aneurysm have been described) and are detected as an incidental finding on 
ultrasonography, abdominal computed tomography or magnetic resonance imaging 
performed for other purposes. Approximately 30% of AAAs are diagnosed through 
clinical examination of the abdomen. Rupture and thromboembolic events are the 
complications most feared, with only approximately 20% of ruptured AA patients 
reaching emergency services alive. Peri-operative mortality for open and endovascular 
repair of AAA in the UK was reported at 7.9 % and 1.7 % respectively5. 
 
An attempt has been made to improve peri-operatve AAA repair mortality with the 
introduction in 2009 of a framework for improving the results of elective AAA repair6. 
The framework, which emphasizes the importance of risk stratification, advised that all 
patients should undergo standard preoperative assessment and risk scoring. Certainly, in 
the last decade we have witnessed a decrease in peri-operative mortality, predominantly 
as a result of endovascular repair being established as a preferred treatment for AA 
when feasible. Yet this comes at the cost of patients needing lifelong follow-up and 
higher re-intervention rates being reported.    
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The introduction of aneurysm screening programmes in North America and Europe has 
led to a greater awareness of this disease, with an increased number of new diagnoses. 
The United States Preventive Services Task Force recommended that men between the 
ages of 65 and 75 years who have ever smoked should be screened at least once for 
AAAs by abdominal ultrasonography7. The increase in surveillance is creating demand 
for further risk stratification whilst intensifying the need to develop strategies for 
retarding growth rate in small aneurysms.  
 
In 2001, the Vascular Biology Research Program of the National Heart, Lung and Blood 
Institute summarized AAA pathogenic mechanisms into four broad areas: “proteolytic 
degradation of the aortic wall connective tissue, inflammation and immune response, 
molecular genetics and biomechanical wall stress”8. More recently, Nordon and 
colleagues investigated three possible models of AAA pathogenesis not mutually 
exclusive:  “AAAs secondary to a local disease process confined to the abdominal aorta 
resulting from atherosclerosis; a systemic dilating diathesis primarily governed by 
genotype; and diseased vascular tree as a consequence of a chronic inflammatory 
process. They concluded that the evidence points to AAA disease being a systemic 
disease of the vasculature, with a predetermined genetic susceptibility leading to a 
phenotype governed by environmental factors"9. AAAs are therefore referred to by 
some researchers as a degenerative disease. 
 
AAAs are associated with atherosclerosis, transmural degenerative processes, 
neovascularization, degeneration of vascular smooth muscle cells (VSMC), and chronic 
inflammation, mainly located in the outer aortic wall10. The variability of local 
haemodynamic factors and intrinsic characteristics along the arterial segment of aorta 
have also been suggested as important factors in aneurysm disease and progression11. 
Observational evidence also suggests that intraluminal thrombus (ILT), together with 
adventitial angiogenic and immune responses, play important roles in the evolution of 
atherothrombosis from the initial stages through to clinical complications, which 
include the formation of aneurysms12. The role of ILT in AA pathogenesis merits 
further discussion and will be explored later in this chapter. 
 
The influence of reported AA risk factors is unknown. More AAAs are being diagnosed 
than ever before, despite efforts in smoking cessation and an increased incidence of 
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diabetes with a suggested protective benefit. Other factors commonly associated with 
aneurysm formation include family history, advanced age, male sex, hypertension, 
aortic dissection and arteriosclerosis. The significance of AA risk factors will be further 
explored in this chapter. 
 
In developing the background to this thesis the following review will fall into nine 
areas: 
1.1 Morphology 
1.2 Structural considerations 
1.3 Genetic concepts 
1.4 Biomechanical concepts 
1.5 Proteolytic considerations  
1.6 Inflammation 
1.7 Risk factors 
1.8 Intraluminal thrombus 
1.9 Summary 
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1.1. MORPHOLOGY OF AORTIC ANEURYSM 
 
1.1.1. Classification 
In general aneurysms are classified into true and false aneurysms. True aneurysms 
involve dilatation of all three layers of the vessel wall, namely, the intima, media and 
adventitia.  All layers of the vessel wall are not involved with false or pseudo 
aneurysms, in which often an association with trauma has been described. 
 
1.1.2. Shape and tortuosity  
The most prevalent aneurysms are characterized by symmetrical enlargement of the 
whole circumference and are therefore referred to as fusiform aneurysms. Aneurysms 
that affect only segments of the arterial circumference are named saccular aneurysms. 
These eccentric aneurysms are more likely to rupture than fusiform aneurysms. 
Therefore, some researchers advocate that the evaluation of AAA rupture risk should be 
based on the accurate quantification of aneurysmal sac shape and size 13. Interestingly, 
FEA analysis of an axisymmetric and fusiform AAA model found that maximum stress 
was a function of the shape of the AAA wall rather than its diameter14. In an FEA 
analysis of a non-aneurysmal model, Vorp et al also confirmed that wall stress was 
greatly dependent on the shape as well as the size of the aneurysm15. Fillinger et al 
observed that ruptured AAAs (matched for age, gender and diameter) are less tortuous 
with greater cross-sectional diameter asymmetry16. Furthermore, existent calcifications 
may influence AAA shape, thus AAA calcification should be considered in 
computational wall stress analyses17.  
 
1.1.3. Diameter  
Currently, the maximum diameter of the aneurysm is the cardinal determinant of AAA 
rupture and therefore used as surrogate for intervention. Contemporary information on 
the rupture risk of larger aneurysms has been derived from the non-surgical arm of the 
US aneurysm detection and management (ADAM) Veteran Affairs Cooperative 
Study18. In this study, which reported a substantial rupture rate for high-operative-risk 
patients with AAA of at least 5.5cm, the participant numbers were small (n=198). A 
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statement from the Joint Council of the American Association for Vascular Surgery and 
Society for Vascular Surgery19 estimated the annual rupture risk according to AAA 
diameter.  
 
Table 1.1 Annual estimated rupture risk 
Initial aneurysm diameter Annual risk of rupture (%) 
< 4.0  0  
4.0-4.9 0.5 – 5  
5.0–5.9 3 – 15 
6.0–6.9 10 – 20 
7.0–7.9 20 – 40 
>8.0 30 – 50 
 
A recent systematic review concluded that rupture rates of small AAAs appear to be low 
with a range between 0 to 1.61 ruptures per 100 person-years20. However, most studies 
have been poorly reported and lacked clear ascertainment and diagnostic criteria for 
aneurysm rupture20.  
 
1.1.4. Expansion rates 
A recent study identified a bimodal growth pattern for AAA, with a significant 
association between annual AAA expansion of 2 mm or more and future intervention or 
rupture21. Choke et al reviewed and reported on AAA expansion rates22. Risk of aortic 
rupture relates to both aneurysm size and the rate of expansion23. This finding was 
confirmed by demonstrating a significantly greater mean AAA enlargement rate in 
patients with probable rupture than patients without rupture (75 vs 41mm per year)18. 
Other researchers also reported increased mean and median expansion rates in patients 
with ruptured AAA compared to patients without rupture (84 vs 39 mm per year)24. 
Expansion rate as an exponential function of initial aneurysm diameter has been 
suggested25, and supported by other researchers23, 26-28. It was observed that final 
aneurysm size was predicted by initial size, suggesting expansion rate was dependent on 
initial AAA diameter, so that 3–6cm diameter aneurysms expanded by 10% of their 
diameter per year25. Limet et al23 also reported more rapid growth in larger diameter 
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aneurysms (5.3mm/year for AAA diameters less than 40mm versus 7.4mm/year for 
AAA diameters of 50mm or more). Conversely, a large observational study of AAAs of 
3.0cm to 3.9cm reported slow expansion with no rupture detected in 1445 patients29. A 
large series of patients with similar aneurysm sizes but varying expansion rates would 
need to be followed without intervention in order to establish if expansion rate 
independently predicts rupture. Furthermore, it is well recognized that AAAs have 
periods of stability, and of gradual and accelerated growth, increasing the difficulty of 
predicting individual expansion rates30. Other variables that have been shown to have a 
positive correlation with expansion rate are pulse pressure25, systolic and diastolic blood 
pressures31 and smoking32. Interestingly, the ADAM (2002) study reported that diabetes 
was negatively associated with aneurysm expansion. A large cohort study reported 
lipid-lowering drug treatment and initial AAA diameter appear to be independently 
associated with lower AAA growth rates33. Furthermore, A PET stand-alone study 
observed a possible association between increased 18F-FDG uptake and AAA expansion 
and rupture34. This suggests that inflammation may be an important factor in aneurysm 
progression. 
 
1.1.5. Calcification 
Maier and co-workers defined calcifications as “heterogeneously distributed, non-
fibrous, stiff plaques which are most commonly found near the luminal surface in 
between the intima and the media layer of the vessel wall”17. The relationship between 
atherosclerosis and vascular calcification is well known35. A study of the thoracic aorta 
in cancer patients demonstrated 18F-FDG vascular uptake was common on PET/CT and 
correlated with vascular calcifications, although the specific sites rarely overlapped36. 
This could suggest inflammation and calcification as different stages in the evolution of 
atheroma. Lindholt suggested that the calcification content in small AAA predicts the 
natural history of small AAA37. This study conducted with serial ultrasound found the 
mean annual growth rate to be significantly lower in men with an AAA wall 
calcification above 50% compared with those  having below 50% (1.72mm versus 
2.97mm, p=0.001)38. Other researchers have found no influence of aortic calcification 
on AAA expansion39.  
 
 32 
 
 Chapter 1 Aortic aneurysm pathogenesis 
The relationship between calcification and AAA peak wall stress has been described40, 
41. Calcification may decrease the biomechanical stability of aneurysmal aorta, since 
AAA calcification increases peak wall stress40. However, some researchers are not 
convinced of an increased rupture risk for AAAs with a high calcium burden17. In 
contrast, it is also suggested that intraluminal thrombus decreases maximum wall stress 
in AAA. Therefore, calcification and intraluminal thrombus should both be taken into 
account when wall stress for risk assessment of AAA rupture is evaluated40. 
Furthermore, the location and shape of the calcified regions, not  only the relative 
amount, are considerations that influence  wall stress in AAA41. AAA calcification not 
only possibly influences expansion but also affects sac regression after repair42. The 
correlation between MMP-mediated elastin degradation and vascular calcification 
suggests inflammation as a major role-player in AAA calcification and pathogenesis43.  
 
1.2. STRUCTURAL CONSIDERATIONS IN AORTIC ANEURYSM 
 
Multiple factors rather than a single process are implicated in AA pathogenesis. These 
factors result in damaging structural changes involving the media and adventitia of the 
aneurysm wall that eventually progress to aneurysm formation and potential rupture 
(Figure 1.1). The media consists of several elastic laminae and vascular smooth muscle 
cells (VSMCs) embedded in a ground substance, whereas fibroblasts, loose connective 
tissue, collagen fibres and vasa vasorum collectively form the adventitia. AAA wall 
integrity is dependent on a balanced remodelling of elastin, collagen and VSMCs as 
predominant constituents of the extracellular matrix (ECM)44, 45. 
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Figure 1.1 Chain of biological events leading to abdominal aortic aneurysm rupture 
[Reproduced with kind permission from the Elsevier Publishing Group, Alexander et al. Figure 1.
46
] 
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1.2.1. Elastin 
The chief component of the media is elastin, a lamellar ECM protein consisting of 
soluble tropoelastin monomers. Elastin production by the VSMCs ceases when a patient 
reaches maturity, therefore these soluble tropoelastin monomers, which are cross-linked 
by lysine residues, have a half-life of 40 to 70y47. This could explain the elderly 
predisposition to AA formation. Normally, more than 99% of total elastin in arteries is 
found in an insoluble cross-linked form that can be stretched as much as 70% of its 
initial length48. Elastin is responsible for the load-bearing property that behaves 
uniformly in both the circumferential and longitudinal directions at different locations 
across the wall thickness, thereby absorbing oscillating arterial shock waves, providing 
recoil and maintaining arterial structure49. Treatment with elastase causes lamellar 
disruption and, results in aneurysmal dilatation, thus emphasizing the importance of the 
lamellar structure in providing resilience to the aortic wall48. 
 
1.2.2. Collagen 
Collagen is the dominant structural component of the arterial adventitia and to a lesser 
extent is found in the media. It is a stable triple helix composed of three polypeptide 
chains with repeating tripeptide sequences and is responsible for tensile strength and 
resistance of the vessel wall50. In contrast to elastin, collagen is synthesized on a 
continual basis throughout life, so collagen content represents the net effect of synthesis 
and degradation51. Type 1 fibrillar collagen accounts for aortic wall load-bearing 
capability (over 20 times greater than that of elastin), while Type 3 collagen provides 
some extensile stretch52. Arterial distension in response to increasing intraluminal 
pressures is limited through the recruitment of inextensible collagen fibres53. Structural 
damage occurs when collagen is extended beyond 2–4% from its uncoiled form54. 
 
1.2.3. Vascular smooth muscle cells (VSMCs) 
VSMCs are important structural elements of the ECM that govern AA disease by 
producing transforming growth factor-beta (TGF-beta1), components of ECM and 
proteases55, 56. VSMCs undergo morphological cell changes from a contractile to a 
synthetic phenotype to produce substances important in remodelling the vascular wall 55. 
This change in morphology is associated with a loss of myofilaments and the formation 
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of extensive rough endoplasmic reticulum and a large Golgi complex. This was verified 
by an experimental study that reported cultured VSMCs from AAAs exhibited greater 
elastolytic activity than VSMCs from aortic occlusive disease (AOD)57. VSMC density 
depends on patient age, patient gender and the location of quantification in non-
atherosclerotic aneurysms. Conversely, loss of VSMCs is a characteristic of 
atherosclerotic aortic aneurysms11, 58. In particular VSMC apoptosis has been associated 
with fibrous cap thinning, enlargement of the necrotic core, plaque calcification, medial 
expansion and degeneration, elastin breaks, and failure of outward remodelling59. In 
addition, chronic VSMC apoptosis may mimic multiple features of medial degeneration 
seen in a variety of human pathologies59. 
 
1.2.4. Experimental and clinical studies  
Histological examination of aneurysms reveals a thinning of the media, disruption of the 
medial connective tissue structure, and the loss of elastin60 culminating in the 
effacement of the lamellar architecture61. The role of the aortic media in contributing to 
wall stability is emphasized through studies demonstrating AA formation following 
media destruction with surgical resection, freezing, or the injection of acetrizoate or 
other noxious agents62. 
 
Other studies confirmed that both elastin and collagen content is decreased in AA walls 
with increased collagen cross-links63 and an increased collagen to elastin ratio64.  Loss 
of elastin appears to be accompanied by an increase in the collagen content of the 
arterial wall, resulting in an overall decrease in the elastin to collagen ratio65. This 
reflects in experimental studies that suggest that aortic elastase secretion is significantly 
higher in patients with AAAs, multiple aneurysms, and ruptured AAAs compared with 
occlusive aorta disease64. Also different expressions of aortic wall elastase and its major 
serum inhibitor, alpha 1-antitrypsin are found in various types of infrarenal aortic 
disease64. 
 
AA development is characterized by intial elastin fragmentation responsible for 
aneurysmal elongation and tortuosity. Researchers agree that remodelling causes 
aneurysmal wall thickening as a result of aorta dilation secondary to elastin loss and 
media structural changes. Early stages of aneurysm formation are characterized by 
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increased collagen synthesis, which suggests a repair process66. As the load bearing 
increases, more uncoiled collagen is recruited to load bear circumferentially67 resulting 
in a less distensible vessel. Collagen, because of its structural properties, must fail for 
significant dilatation and rupture to occur. This is confirmed as patients who are post 
aortic endarterectomy rarely incur AA disease.  Dobrin et al concluded that both elastin 
and collagen are possibly critical in AA dilatation with collagen failure resulting in 
gross expansion and rupture44. This work confirmed experimental studies demonstrating 
that application of elastase caused arterial dilatation and stiffening, whereas application 
of collagenase leads to arterial rupture without dilatation64. Cohen suggested that elastin 
degradation is a key step in the development of aneurysms, but that collagen 
degradation is responsible for aneurysm rupture64. 
 
It has been shown that certain disease states, such as inflammation, arterial trauma, 
medial stress, and normal ageing, can induce elastolysis, which results in reduced 
compliance of the aorta, increased wall stiffness, and increased stress68, 69. It is 
suspected that persistent haemodynamic, oxidant, or other forms of stress could induce 
elastin damage and initiate dysfunctional remodelling of the wall through the stretch-
induced production of atypical collagen and elastin by VSMCs. Ineffective 
elastogenesis by VSMCs and macrophages is demonstrated in an experimental study 
where the AA group showed 9-fold lower levels of desmosine, a marker of mature, 
cross-linked elastin, and a 4- to 6-fold increase in levels of tropoelastin as compared 
with normal aortas45. Impairment of the remodelling of new collagen and elastin may 
render these components more susceptible to further enzymatic degradation70, 71. The 
integral role of VSMCs in AA disease is confirmed by an animal study that observed 
AAA prevention and regression after infusion with VSMCs 72. 
 
1.3. MOLECULAR GENETICS IN AORTIC ANEURYSM  
 
Genetic factors have been shown to play a role in the aetiology of AA even when they 
are not associated aortic syndromes 73. The genetic basis of aortic aneurysms was 
reviewed in 199174. The major determining factor in the appearance of aortic aneurysms 
may be an inborn defect of collagen type III or of another component of the connective 
tissue matrix. At least 20% of aneurysms result from inherited disorders75.  
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1.3.1. Historical background  
Coady and co-workers summarized the historical background of AA76. The majority of 
work on the genetic factors involved in AA is from AAA studies. Clifton was the first to 
identify a familial aggregation of AAA, describing 3 male siblings who presented and 
were treated for ruptured aneurysms 77. A later paper reported 1 or more first-degree 
relatives in 50 families with AAA78. Several AAA genetic models were studied to 
underpin the familial nature of the disease78-81.  These studies confirmed AAA as a 
common  familial disease with 18 out of 100 patients having a first-degree relative with 
the disease82. For most patients, however, the cause of the aortic aneurysm remains 
unknown76, 83.  
 
1.3.2. Genetics considerations  
Genetic factors in AAAs have been implicated by the above-mentioned and other 
studies, the presence of multiple aneurysms and by systemic abnormalities in AA 
patients such as association with connective tissue disease. AAA genetic screening 
studies suggest an odds ratio of 1.9 to 2.4 with 20% of males likely to develop AAA if 
they have a first-degree relative with the disease84. To a lesser extent, researchers have 
focussed on AAA families with at least 2 affected members and suggested genes located 
on chromosome 19q13 and 4q31.4785, 86. Genes implicated in these territories include 
interleukin (IL)-15, endothelin receptor A, programmed cell death 5, and LDL receptor-
related protein 3.4773. AA and association with genetic disease is summarized in Table 
1.2. 
  
 38 
 
 Chapter 1 Aortic aneurysm pathogenesis 
Table 1.2 Genetic disease and aortic aneurysm 
Affected Aortic 
Segment 
Familial disorder Mode of inheritance Gene 
linked  
Ascending, thoracic or 
abdominal 
Ehlers-Danlos syndrome 
type IV 
  
Autosomal dominant COLA3A1 
Ascending Marfan Syndrome Autosomal dominant FBN1 
TGFβR2 
 Turner Syndrome Chrosomal   
 Osteogenesis imperfecta Autosomal dominant COLA1A1 
Thoracic Autosomal 
dominant adult polycystic 
kidney disease 
Autosomal dominant PKD1,PK
D2 
Abdominal Homocystinuria Autosomal recessive CBS 
 Pseudoxanthoma 
elasticum 
Autosomal recessive ABCC6 
 
1.4. HAEMODYNAMIC FACTORS AND BIOMECHANICAL WALL STRESS CONSIDERATIONS IN 
AORTIC ANEURYSM  
 
Contrary to current understanding of certain biological, biochemical and morphological 
factors, the role of biomechanical factors in AA pathobiology is poorly understood. 
Researchers recognize that when the stress acting on the AAA wall exceeds the strength 
of the wall it can cause continuous expansion, dissection and rupture. Li and co-workers 
advocate wall-stress simulation based on a patient-specific AAA model as a more 
accurate rupture risk stratificator than AAA diameter alone87.  
 
1.4.1. Haemodynamic forces 
Sprouse et al identified three distinct fluid-induced forces on the artery wall: (1) 
pressure created by hydrostatic forces, (2) circumferential stretch exerting longitudinal 
forces, and (3) shear stress created by the movement of blood88. The net force includes a 
component perpendicular to the wall, the pressure, and a component along the wall, the 
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shear stress. Endothelium damage and accelerating degeneration of the arterial wall as a 
result of turbulence and other flow factors contribute to aneurysm expansion. 
Furthermore, high and low shear stress and areas of flow oscillation are implicated in 
aortic atherosclerosis development89. Although clinical studies demonstrate that blood 
flow within AAAs can be smooth and laminar or irregular and turbulent, the effects of 
wall shear stress in aneurysms remain to be established90. 
 
Zeng and co-workers identified factors affecting intra-aneurysmal flow such as the 
geometry of the aneurysm sac and surrounding vasculature, including the existence, 
size, and symmetry of branches arising near the aneurysm, and the position of the 
aneurysm sac relative to the parent vessel (eg, sidewall, terminal, or bifurcation). Effort 
has been made to correlate rupture with these various geometric features91.  
 
1.4.2. Haemodynamic forces effect on aneurysm expansion  
Aneurysm endothelium is constantly exposed to dragging force of blood shear stress.  
The focal development of atherosclerosis in haemodynamically defined areas (regions 
of branched and curved arteries exposed to disturbed flow conditions as opposed to 
straight arteries) emphasizes the role of shear stress in vascular pathophysiobiology92. A 
dominating factor identified in vessel remodelling is alteration in blood flow 93. Arterial 
remodelling is hampered by wall shear stress increases (causing vascular inflammation 
and wall thickening) but encouraged by decreases in arterial wall shear stress94, 95. Also, 
degradation of the internal elastic lamina (IEL) is caused by a low wall shear stress96. 
However, this process of how proteases are influenced by wall shear stress remains to 
be defined93. 
 
Furthermore, mechanical forces can increase or decrease gene activation in the blood 
vessel wall. For example, in cultured human endothelial cells, laminar shear stress 
increases expression of superoxide dismutase and endothelial nitric oxide synthase, 
whereas turbulent shear stress does not induce these protective genes97. Mechanically 
induced genes contain positive and negative shear stress responsive elements in their 
promoter regions, such as antioxidant response element (ARE) that functions to protect 
cells against oxidant stress98. 
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The increase in shear stress has been linked with a decrease in reactive oxidative s tress 
(ROS). The pathway of this reduction in ROS is mediated by haemoxygenase (HO-1) in 
macrophages rather than by the inflammatory response. In order to survive exposure to 
environmental stresses this adaptive cellular response HO-1 expression exists99.  
 
Given the beneficial effects of flow loading on vessel remodelling in AAA, it may be 
surprising that shear stress does not reduce expression of MMP-2 or MMP-9. However, 
because ROS activates latent proforms of MMPs in the vascular interstitium, reduction 
in oxidative stress may nonetheless result in decreased MMP activity100.   
 
To overcome biomechanical design limitations of in vitro AAA models, Miller et al 
suggested experiments in animal models. Unfortunately, controversy exists regarding 
appropriate animal models of human AAAs98.  
 
1.4.3.  Haemodynamic forces effect on aneurysm rupture  
Rupture of the aneurysm has been described as a structural failure when the induced 
mechanical wall stresses exceed aneurysmal wall integrity. Several concomitant factors 
(including aneurysm shape and tortuosity, wall constituents, ILT characteristics and the 
interaction between the fluid and solid domains) associated with blood pressure and 
shear stress are indicated in AA rupture87 and have been evaluated in the past15, 101-103.   
 
1.4.4. Current limitations 
Accurate wall strength measurement in vivo is currently not possible. This may affect 
computed wall stress estimation, since wall stress at a certain time point is dependent on 
wall strength at that point for rupture to occur. However, wall stress analysis based on 
serial images may be more useful in depicting aneurysm stability87.  
 
1.5. ENZYMATIC ACTIVITY IN AORTIC ANEURYSM  
 
Proteolytic degeneration is known to cause AA formation and lead to disease 
progression. Proteases identified in excess in AA and other aortic diseases include 
matrix metalloproteinases (MMPs), cathepsins, chymase and tryptase, neutrophil -
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derived serine elastase, tissue plasminogen activator (tPA), urokinase-type plasminogen 
activator (uPA) and plasmin104. These proteolytic enzymes are involved in regulating 
and remodelling the ECM. 
 
1.5.1. Experimental and clinical studies  
Pioneering work in animal models has demonstrated the role of proteolysis in AA. 
These experimental studies showed elongation and dilatation following treatment with 
elastase, and rupture post collagenase infusion. More recently, an in vivo study of aortic 
wall treated with doxycycline-loaded, controlled-release, biodegradable fibre led to 
preservation of elastin content, decreased MMPs (most notably MMP-2 and MMP-9) 
and increased tissue inhibitor of metalloproteases (TIMP-1)105. The media of the AAA 
host increased levels of several MMPs, including elastases, collagenases, gelatinases 
and stromelysin. The release of these proteases (derived from macrophages and VSMCs 
into ECM is caused by stimulation by the products of elastin degradation106. 
Inflammatory infiltrates and invading neovessels are relevant sources of MMPs in the 
AAA wall and may substantially contribute to aneurysm wall instability107. Histological 
studies reported elastases MMP-2, MMP-9, and MMP-12 have increased expression in 
aneurysmal aortic tissue108. Also higher levels of collagenases MMP-1 and MMP-13 in 
human AAAs have been linked with structural collagen degradation109. Despite 
evidence in animal models of the crucial involvement of MMP-9 in AAA formation and 
growth, the pivotal role of MMP-9 in driving human AAA growth is debated. It has 
been suggested that additional proteases such as MMP-8 and the cysteine proteases 
cathepsin K, L, and S may also play central roles110. These and other studies confirm the 
significant role that MMPs and their substrates play in AA formation. In AA disease 
evidence suggests that the equilibrium of vessel wall remodelling between MMPs, 
TIMPS and other protease inhibitors is disrupted, resulting in elastin and collagen 
degradation, with the net pathobiological effect of ECM destruction.  
 
1.5.2. Gelatinases 
1.5.2.1. MMP-9 (92-kd gelatinase) 
MMP-9, predominantly secreted by macrophages, monocytes and VSMCs, is the most 
comprehensively studied of the metalloproteases. MMP-9 concentrations are higher in 
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patients with AAA compared to subjects without AAA or AOD. Interestingly, Takagi 
observed that increased MMP-9 serum levels return to normal after aneurysm repair111. 
Furthermore, an experimental study showed that targeted gene disruption of MMP-9 
prevented aneurysmal degeneration in murine models112. More recently, a correlation 
was found between AAA rupture and elevated plasma levels of MMP-9 and MMP-1113.  
 
1.5.2.2. MMP-2 (72-kd gelatinase) 
Evidence suggests MMP-2 may be the most integral protease in ECM degeneration. 
MMP-2, found predominantly in its active form (62-kd), is sourced by adventitial 
VSMCs and fibroblasts and is uniquely activated by membrane type (MT)-MMPs. 
MMP-2 can degrade both elastin and collagen and may be responsible for early AA 
development. MMP-2 also complements and facilitates MMP-9 activity in transgenic 
murine models. However, some researchers suggest that MMP-2 may have greater 
elastolytic activity compared to MMP-9. Increased MMP-2 expression has been 
observed in subjects with AAA compared to those with AOD or without AAA 
disease114. Convincing evidence from a rat aneurysm model demonstrated that the 
inhibition of AA formation following TIMP-1 over-expression, resulted in an activation 
blockade of both MMP-2 and MMP–9115. Furthermore, other researchers concluded 
patients with larger aortic diameters have increased MMP-2/TIMP-1 ratios116.  
 
1.5.3. Elastases 
1.5.3.1. MMP- 3 
Matrix metalloproteinase-3 (MMP-3) also degrades the ECM and perhaps aids 
ascending thoracic aorta development117. MMP-3 gene inactivation in mice 
demonstrated that MMP-3 possibly causes degradation of matrix components, and 
promotes aneurysm formation by degradation of the elastica lamina118.  
 
1.5.3.2. MMP-12(54-kd macrophage metalloelastase) 
MMP-12 is involved in AA pathogenesis and shows a high affinity for elastin. In its 
active form the 22-kd enzyme degrades elastin119. A study on AA development in 
apolipoprotein E-knockout mice reported MMP-12 predominance in elastolytic activity. 
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 Deficiency of MMP-12 in the mice conferred protection against medial destruction and 
ectasia120.  
 
1.5.4. Collagenases 
Increasing collagenolytic activity has been identified in AAs; however, collagen 
proteolysis is mostly associated with the terminal event of AA rupture. This is 
confirmed by greater levels of activity measured in specimens of ruptured aneurysms 121.  
 
1.5.4.1. MMP-1 (Collagenase-1)  
MMP-1 localizes within the mesenchymal cells (VSMCs, fibroblasts and endothelial 
cells) and is up-regulated by inflammatory mediators; however, macrophage 
involvement has been described.  Increased pro-MMP-1, MMP-1 protein and mRNA 
levels have been reported in AAA compared to healthy aorta122.  
 
1.5.4.2. MMP-8 (Collagenase-2) (matrilysin) 
Studies report inconsistent expression of MMP-8 in AOD and AAA tissue; however, 
MMP-8 is stored as pre-formed protein in granules. Therefore MMP-8 mRNA may not 
accurately reflect protein concentration. Prominent expression of MMP-8 has been 
described in acute aortic dissection123.  
 
1.5.4.3. MMP-13 (Collagenase-3)  
MMP-13 is closely spatially related to VSMCs and collagen. Mao et al observed higher 
expression of MMP-13 in AAA compared to AOD tissue109.  
 
1.5.5.  Inhibition of MMPs  
Primary control of the activity of MMPs is achieved through tissue inhibitor of 
metalloproteinase (TIMP), by the formation of non-covalent complexes22. TIMP-2, a 
broad-spectrum MMP inhibitor, and PAI-1, an inhibitor of tPA and uPA, are less 
expressed in AAA walls than in AOD, suggesting that ECM destruction is caused by a 
decrease in inhibitors and an increase in proteases104. Alpha-1-antitrypsin and alpha-2-
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macroglobulin may suppress elastolysis, which is responsible for 90% of the inhibition 
of circulating MMPs124. Treatment with atorvastatin decreases MMP expression and 
activity and leads to a reduction of TGF-beta signalling in the central region of human 
AAAs125. Also ezetimibe combination therapy decreases aortic wall inflammation 
implicated in AAA expansion126.  
 
1.6. INFLAMMATORY CHANGES IN AORTIC ANEURYSM 
 
AA is best described as a chronic inflammatory condition with an associated proteolytic 
imbalance. The most important pathological feature of human AA is probably the 
presence of a chronic inflammatory infiltrate consisting predominantly of macrophages, 
plasma cells and lymphocytes. These inflammatory cells and others mediate this chronic 
inflammatory process through the release of cytokines that allow for increased protease 
expression, expression of cell adhesion molecules, and the release of ROS causing 
degradation of the ECM through the activation of MMPs and TIMP 127. 
The recruitment of macrophages by chemotactic agents is possibly triggered by exposed 
elastin degradation products, whereas lymphocyte stimulation may be triggered by 
micro-organisms and auto-antigens from structural degradation. Interferon (INF)-
gamma and tumour necrosis factor (TNF)-alpha appear to be the most consistently 
expressed cytokines in patients with large AAAs128. Furthermore, these inflammatory 
cytokines play multiple roles in regulating mesenchymal cell matrix metabolism, 
endothelial cell growth and proliferation, lymphocyte activation, antigen presenting cell 
(APC) function, major histocompatibility (MHC) class II molecule expression, vascular 
adhesion molecule expression, and even matrix degrading protease expression of 
surrounding cells129. 
 
Although AA and AOD are characterized by underlying inflammation, 
immunohistological studies have concluded that T- and B-cell predominance is 
localized to the outer media and adventitia in AA, compared to largely T–cell 
involvement localized to the intima and inner media in AOD. Furthermore, an 
autoimmune component to AA disease has been suggested after localization of B-
lymphocytes in the media and considerable deposits of immunoglobulins (IgG) and 
complement proteins in the wall of AA10.  
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1.6.1. Experimental and clinical studies  
Key features of human AA include intense inflammation, increased expression of 
MMP-2 and -9, and local ECM destruction. Inflammation as integral role player in 
aneurysm pathogenesis was identified following breakthrough experimental animal 
models that demonstrated key features of human aneurysm following transmural 
chemical injury induced by calcium chloride treatment of the adventitia layer of the 
vessel. Interestingly, researchers advocate that aneurysm development secondary to 
chemical and mechanical injury is caused by inflammation, rather than direct elastolysis 
since aneurysm formation only developed after the inflammatory response was present. 
The calcium chloride murine model further indicates that CD4+ lymphocytes may be 
central in orchestrating production of MMP-2 and MMP-9 through interferon gamma130,  
131. Researchers recognized that elastase exposure of the aorta wall caused elastin 
degradation with up to a 421% increase in AA diameter six days post treatment 132. This 
aorta diameter increase was also associated with media infiltration of a large number of 
activated macrophages and T-cells132. From the elastase infusion model we also learned 
that the inflammatory cell infiltrate is accompanied by greater expression of MMP-2 
and MMP-9. Inhibition of the arachidonic acid metabolites by indomethacin has proved 
inhibition of both recognized MMPs in AA formation and progression. Doxycycline, a 
tetracycline derivative, is also found to be effective in inhibiting these integral MMPs. It 
has been shown to reduce aneurysm formation in both the calcium chloride and elastase 
infusion animal models; however, additional clinical studies are needed to clarify its 
role in the progression of human AA133. Interestingly, Choke and co-workers observed 
that ruptured areas on immunohistochemistry have significantly increased amounts of 
immature micro-vessels, with an excess of MMPs and to a much lesser extent 
infiltration of macrophages and T-lymphocytes134. 
 
Furthermore, the influence of prostaglandins and leukotrienes in the 5-lipoxygenase 
pathway has been suggested as a potential mechanism in AAA formation, since 
deficiency of 5-lipoxygenase attenuates aneurysm formation of atherosclerotic 
apolipoprotein E-deficient mice66.  
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1.6.2. Inflammatory cells involved in aortic aneurysm 
1.6.2.1. Lymphocytes 
 It is suggested that T-helper (Th)1 and Th2-restricted T lymphocyte are the most 
commonly found immunological cells in AAA walls and are activated by antigen 
presenting cells such as macrophages, VSMCs, and endothelial cells10. These 
inflammatory cells are integral for mediation of the immune response in AAA. 
However, the specific regulatory traits of components of the inflammatory cascades and 
of proteases that cause aneurysmal growth remain largely unresolved. This reflects in 
earlier mouse studies which designated AAA disease as a Th-2-type inflammatory 
disease and identified Th-2-restricted CD3C T as the dominant influx. Later human 
studies suggested differently with AAA disease labelled as Th1-dominated or as a 
general pro-inflammatory condition135. Local secretion of Th1 cytokines INF-gamma, 
Interleukin-2 (IL-2), IL-12, IL-15 and IL-18) may enhance macrophage expression of 
MMPs, whereas Th2 cytokines (IL-4, 5, 8, and 10, TNF-alpha, INF-gamma and CD40 
ligand) possibly inhibit macrophage MMP production and may constrain disease 
progression10. In addition, T-helper (Th)-2 cells secrete an FAS-ligand and Fas-
associated phosphatase-1 resulting in apoptosis of VSMCs and Th1 cells136. Cytokines 
TNF-alpha and IL-8 cause inflammatory cell recruitment that is responsible for 
stimulating neoangiogenesis. INF-gamma stimulates cathepsin production for further 
Th2 activation, B-cell differentiation and Ig secretion10. 
 
In addition to regulating the immune response and cell apoptosis, Th2-cells also 
produce IFN-gamma, as well as CD40 ligand137. This is supported by animal studies 
showing that mice lacking IL-4, IL-10 or CD4 develop larger elastase induced 
aneurysms compared to common mice. However, no significant effect on AAAs has 
been observed in mice with IFN-gamma deficiency. Others have found that CD4-
deficient mice do not develop experimental aneurysms, unless IFN-gamma is 
administered. This could indicate that Th1-type immune responses are essential in 
aneurysmal disease, and that shifting the cellular immune response from domination of 
Th1 cytokines to one that favours Th2 cytokines, could in theory suppress aneurysmal 
degeneration137. 
 
In most cases, the default pathway will be a Th1-dominant for stenotic arterial lesions; 
 47 
 
 Chapter 1 Aortic aneurysm pathogenesis 
however, when the local environment is skewed toward Th2 predominance, aneurysms 
will develop66. More recently a study comparing inflammatory and proteolytic 
processes in AAA and popliteal artery aneurysm, characterized degenerative 
aneurysmal disease as a general inflammatory condition that is dominated by profound 
activation of the nuclear factor-kappa-B and activator protein-1 pathways with over-
expression of IL-6 and IL-8, and neutrophil involvement135.  
 
1.6.2.2. Macrophages  
Inflammation is characterized by macrophage migration from the onset of AA 
formation. Elastin degradation products are possibly responsible for the recruitment of 
macrophages by chemotactic agents (Figure 1.2). Haemodynamic forces may regulate 
macrophage adhesion, transmural migration and survival138. A recent animal study 
confirmed that MT1-MMP acts directly to regulate macrophage secretion139. This 
antigen presenting cell is suggested to be a central role player in the immune response 
and subsequent ECM destruction. It is mostly localized in the adventitia of the AA wall. 
Through the secretion of cytokines  (IL-1b, IL-6, IL-8, and TNF-alpha) and proteases 
(in particular MMP-9) these macrophages recruit inflammatory cells and stimulate 
cytokine production, protease production, B-cell differentiation, Ig secretion, cytotoxic 
T-cell differentiation and neovascularization10. In addition to producing cytokines and 
proteases, these cells also produce TIMP, confirming the governing role of 
macrophages in AA immune response. Animal studies confirmed the paramount role of 
macrophages in AA inflammatory response by demonstrating human-like aortic 
aneurysmal degradation without further manipulation following the application of 
macrophages and plasmin to the aorta140. 
 
1.6.2.3. Endothelial cells  
Endothelial cells have been localized in AA and are found proximate to 
neovascularization. A prominent role for endothelial cells in the inflammatory response 
has been suggested following histological study reports of a positive association 
between the degree of inflammation and the degree of neovascularization. It is 
suggested that these inflammatory cells play a role in ECM remodelling through the 
secretion of IL-1b and IL-8, which stimulate intercellular adhesion molecule-1 (ICAM-
 48 
 
 Chapter 1 Aortic aneurysm pathogenesis 
1) presentation, thus causing recruitment of additional inflammatory cells, attraction of 
lymphocytes, stimulation of endothelial proliferation, stimulation of B-cell 
differentiation and Ig secretion. In addition, like macrophages, the proliferating 
endothelium also produces various MMPs and TIMP10. To this end an experimental 
study has demonstrated that doxycycline not only inhibits MMP-8 and MMP-9 activity, 
but also the synthesis of MMPs in human endothelial cells141.  
 
 
Figure 1.2 Schematic diagram of the mechanisms implicated in abdominal aortic 
aneurysm, which primarily involve two main processes: inflammation and 
extracellular matrix turnover  
Onset of AAA is associated with recruitment of inflammatory cells to the aortic media, 
macrophage activation, and the production of proinflammatory molecules. The aortic lumen shows 
intraluminal thrombus formation and adhesion of inflammatory cells. Within the AAA vessel wall, 
inflammatory cell infiltration promotes smooth muscle cell apoptosis, elastin degradation, and 
collagen turnover either directly or indirectly (via the production of proinflammatory molecules). 
The AAA vessel wall architecture shows typical changes, including loss of elastin, collagen 
deposition, depletion of smooth muscle cells, and neovascularization. Abbreviations: +, promotes; 
-, inhibits; APC–PCI, activated protein C–protein C inhibitor complex; CRP, C-reactive protein; 
EP, elastin peptide; IFN, interferon; IL, interleukin; ILT, intraluminal thrombus; MMP, matrix 
metalloproteinase; PICP, carboxy-terminal propeptide of type I procollagen; PIIINP, amino-
terminal propeptide of type III procollagen; SMC, smooth muscle cell; TGF, transforming growth 
factor; TNF, tumor necrosis factor; VEGFA, vascular endothelial growth factor A.  
 
[Reproduced with kind permission from the Nature Publishing Group, Hellenthal et al. Figure 1.
142
] 
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1.6.2.4. Fibroblasts  
Although fibroblasts are commonly identified in the adventitia of AAA and have a 
recognized function in atherosclerosis, the role of the fibroblast in aneurysm 
pathogenesis is uncertain. Fibroblasts secrete cytokine IL-6 which is suggested to cause 
a stimulatory cascade of B-cell and cytotoxic T-cell differentiation and MMP 
stimulation143.  
 
1.6.3. Infection and aortic aneurysm   
An infectious cause responsible for aneurysm formation has also been advocated. 
Between 30% and 50% of AAAs are associated with Chlamydia and Herpes virus 
infections.  Chlamydia has been shown to induce AAA in rabbits and antichlamydial 
antibodies are commonly detected in AAA patients; however, a causal relationship 
remains to be established. Studies have suggested that these infections play a role in 
elastolysis, possibly creating and augmenting an autoimmune response through particle 
mimicking. Lindholt et al found that serum antibodies against Chlamydophila 
pneumoniae have been associated with AAA expansion and cross-reaction with AAA 
structural proteins. Thus, immune responses mediated by microorganisms and 
autoantigens may play a pivotal role in AAA pathogenesis144.  
 
1.6.4. Vasculitides and aortic aneurysm   
Vasculitides that affect the aorta are predominantly giant cell arteritis (GCA) and 
Takayasu’s arteritis (TA). These are idiopathic systemic inflammatory conditions 
characterized by granulomatous inflammation of large and medium-sized arteries145. 
The pathogenesis of GCA and TA is poorly understood. It is suggested that cell-
mediated autoimmunity plays an important role, possibly triggered by infectious agents. 
The histological appearance is of a focal panarteritis. The transmural inflammatory 
infiltrate is largely composed of lymphocytes, macrophages and multinucleated giant 
cells, which may be organized into granulomas. The cellular infiltrate in TA tends to 
localize to the adventitia and outer parts of the media can lead to aneurysmal dilation. 
Ultimately, intimal proliferation and dense scarring can compromise the vascular lumen 
resulting in arterial stenosis. In GCA, the centre of tissue damage lies at the internal 
elastic lamina. Concentric intimal thickening, partly resulting from oedema, narrows the 
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vessel and luminal thrombosis can occur145. Aortitis due to GCA may lead to 
destruction of the elastic lamina and muscular media causing late aneurysms even in 
those individuals responding well to medical treatment. Aneurysm development may 
also be secondary to isolated necrotizing aortitis. Aneurysm formation as a complication 
is more frequent than vessel stenosis or occlusion146. 
 
New imaging modalities such as colour Doppler ultrasound and positron-emission 
tomography are providing further insights into the extent and pathobiology of large 
vessel vasculitis. It allows for the detection of vessel alterations early on and a better 
control of the disease progression. However, at present temporal artery biopsy and 
angiography remain the gold standards for diagnosis145. 
 
1.6.5.  Aortitis 
Chronic periaortitis is characterized by an inflammatory process involving fibrous tissue 
that arises from the abdominal aorta and the iliac arteries. Historically, chronic 
periaortitis was suggested to be a localized inflammation as part of a severe degree of 
aortic atherosclerosis, however, involvement often extended beyond the aorta including 
other large vessels with or without aneurysmal dilatation. Histopathologic 
characteristics of chronic periaortitis include adventitial inflammation and fibrosis, 
vasculitis of vasa vasorum, and adventitial lymphoid follicles with germinal centres, 
which suggest a primary nature to chronic aortitis147. Recently identified IgG4-related 
inflammatory AAAs (IAAAs) may be part of IgG4 related systemic disease and 
therefore IAAA should be ruled out  in patients diagnosed with aortitis or periaortitis148. 
 
1.6.6. Inflammatory aortic aneurysm  
Since the first description of inflammatory abdominal aortic aneurysm  (IAAA)149, it 
has been estimated that IAAA accounts for 2 – 10% of all AAAs150, 151. Patients with 
IAAA are younger in relation to the rest of the AAA population151 with a strong male 
predominance 152. Some researchers have suggested that IAAA and non-inflammatory 
AAA is one pathological process with varying degrees of inflammation153-155, whereas 
others have postulated an autoimmune and or infectious cause with Chlamydia 
pneumoniae or Helicobacter pylori156-158. Elevated serum IgG levels and autoantibodies 
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such as antinuclear antibody (ANA) are also detected in patients with IAAA159 
suggesting an autoimmune role in the pathobiology160. Systemic inflammatory markers, 
such as erythrocyte sedimentation rate (ESR), C-reactive protein levels and white blood 
counts are commonly elevated in IAAA149.  Symptoms of back pain and, weight loss in 
a patient with an AAA and an elevated ESR, is highly suggestive of an inflammatory 
component161. IAAA radiological characteristics include aortic dilatation, periaortic 
mantle zone, and adhesions to adjacent organs162. This periaortic mantle zone 
microscopically characterizes IAAA and is described as white, glistening, 
perianeurysmal fibrosis149, 163. Histopathological studies observed extensive fibrosis 
with marked thickening of the aortic wall and severe lymphoplasmacytic infiltration that 
predominantly involves the adventitia with extension into adjacent soft tissues164, 165. 
 
Inflammatory cell infiltrates are characterized by macrophages, T-lymphocytes and B-
lymphocytes153, 166, 167.  Furthermore, it is suggested that an imbalance in the ratio of T-
helper cells to T-suppressor cells, with the predominance of T-helper cells stimulating 
macrophages, results in activation and proliferation of B-lymphocytes. Macrophages 
may also act as antigen presenting cells and thus govern the immune response 153. 
Therefore, it is not surprising that in vivo imaging modalities are explored in AAA 
assessment, in particular PET/ CT, to detect inflammatory or metabolic activity in the 
aneurysmal wall and to further delineate the role of chronic inflammation in aneurysm 
pathobiology. 
 
1.6.7. Rupture and inflammation  
MMP activity has been linked with AAA rupture; however, the exact mechanism 
remains to be found. A quantitative immunohistochemistry study demonstrated that 
expression of MMP-8 and -9 was dependent on mesenchymal cells native to the aorta, 
either VSMCs, fibroblasts, or myofibroblasts, rather than inflammatory infiltrate168. 
Furthermore, another immunohistochemistry study found increased medial 
neovascularization and overexpression of alpha(v)-integrin, VEGF, vascular 
endothelial-cadherin, MCP-1, and vimentin at the edge of the site of AAA rupture169. 
 
These inflammatory changes may involve more than just the rupture site. A recent 
immunohistochemistry study observed inflammatory changes in aneurysm biopsies 
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from three distinct sites: 1) stable non-ruptured aneurysms, 2) a non-ruptured site within 
the ruptured aneurysm and 3) the actual site of AAA rupture. Wilson et al concluded the 
biological events leading to AAA rupture may not be dependent on an up-regulation in 
the inflammatory process170. This finding is in keeping with a quantitative analysis of 
macrophages and generic lymphocytes which failed to show an increase at the site of 
aneurysm rupture, suggesting inflammation may have little bearing on the terminal 
process of aneurysm rupture168.   
 
1.6.8. Reactive oxygen species and aortic aneurysm   
Increased concentrations of ROS such as superoxide (O2-) have been observed in human 
AAAs. Increased nitric oxide synthase expression and lower levels of the antioxidant, 
O2- dismutase following experimental aneurysm induction with elastase infusion were 
identified. O2- levels in human aneurysmal tissue are 2.5-fold higher than in adjacent 
non-aneurysmal aortic tissue and 10-fold higher than in control aorta171.  
 
1.7. RISK FACTORS IN AORTIC ANEURYSM 
 
1.7.1. Family history 
Familial aggregation studies have confirmed a positive family history for AAA in 
approximately 15% of patients with AAA who do not have any recognizable connective 
tissue disorder172.  
 
1.7.2. Age 
The process of ageing is known to cause an estimated 15-20% increase in the diameter 
of major arteries at age 65 compared to younger controls173. This change can be 
influenced by factors such as hypertension, body size and sex; and has been linked to 
matrix degeneration. The prevalence of AAA post adjustment for confounding factors 
shows an almost two-fold increase from 2.7% in ages 65-69y to 4.4% at 75-79y, with a 
peak incidence at 65y174.  
 
 53 
 
 Chapter 1 Aortic aneurysm pathogenesis 
1.7.3. Gender 
Men are 5.6 times more likely to develop an AAA compared to females, therefore 
confirming that male sex is the greatest risk factor for AAA174. The prevalence of AAA 
amongst men aged 65-79y was 6.8 per cent. In the pathogenesis of AAA, oestrogen may 
play an inhibitory role by decreasing the expression of MMP-2 and MMP-9 
synthesis175, thus providing a possible explanation for the lower incidence in the female 
sex. Nevertheless, there is a three-fold higher risk of rupture in women compared to 
men when non-randomized patients were included in analysis176. A smaller study found 
the risk of rupture in women with AAAs of 5.0–5.9cm to be four times that of men with 
AAAs of 5.0–5.9cm24. Also, the mean diameter preceding rupture was decreased in 
women (5.0±0.8 cm) compared to men (6.0±1.4cm). Furthermore, McPhee and co-
workers reported a higher percentage of female patients presenting with rupture, and a 
higher mortality rate during hospital stay for both intact and ruptured aneurysm 
presentations177.    
 
1.7.4. Hypertension 
Hypertension alongside chemical induced elastic lamina degradation is used to induce 
aneurysms in murine models178. Clinical studies concluded that hypertension may be a 
factor predisposing to AAA, or it may affect the growth rate or risk of rupture of an 
existing aneurysm174. However, the effect is more pronounced in larger aneurysms. 
Multivariate analysis in one study revealed a marginally significant correlation between 
hypertension and AAA179.  UK Small Aneurysm Trial (UKSAT) furthermore reported 
that aneurysm rupture was associated with higher mean blood pressure176. Researchers 
have also emphasized that diastolic blood pressure was a more accurate predictor of 
aneurysm rupture than systolic blood pressure. Another study reported that of 157 
patients hypertension (>150/100 mmHg) was present in 67% who had ruptured, but in 
only 23% of those without rupture180. 
 
1.7.5. Diabetes 
This cardiovascular risk factor demonstrates a significantly negative association with 
AAA expansion179 with a reduction of over 30% of aneurysm diameter observed by 
some181. Furthermore a large study found a significantly lower prevalence of AAA 
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amongst patients known to have diabetes182. Decreased aneurysm expansion associated 
with diabetes is explained by three suggested theories. Firstly, hyperinsulinaemia causes 
reduced fibrinolysis with less renewal of mural thrombosis, thus affecting progression. 
Secondly, hyperglycaemia causes increased collagen synthesis. This leads to 
decreased synthesis and activity of MMP, resistance to MMP digestion and altered 
VSMC phenotype, facilitating increased wall stiffness. Lastly, therapeutic agents 
decrease inflammation, MMP activity and blood pressure, with a resultant reduction of 
AA expansion. This rather paradoxical association of diabetes with AAA may help to 
explain differing pathogeneses between aneurysmal and atherosclerotic disease.  
 
1.7.6. Smoking 
Cigarette smoking is recognized as one of the most prevalent risk factors and certainly 
the largest avoidable risk factor associated with AA formation, expansion and rupture. 
Lifetime male smokers are 2.5 times more likely to develop AAA than male non-
smokers18, 174. The strength and dose-response of the correlation between the cumulative 
lifetime history of being a smoker and AAA, suggests a causative role in aneurysm 
aetiology. In a hypertension-induced ApoE (-/-) mice study mainstream smoke was 
responsible for both the formation and severity of AAA183. Furthermore, increased 
protease activity was shown when the mice were exposed to a combination of 
angiotensin-II treatment and cigarette smoke183, thereby increasing the degradation of 
aortic connective tissue. 
Shimizu et al studied a subset of patients with aortic atherosclerosis, smoking and/or 
genetic predilection, and found inhibition of local IFN-signalling and/or eliciting Th2-
dominant cytokine environments, thus inducing macrophage elastolytic activity, which 
resulted in AAA formation66. Brady et al furthermore reported a 15-20% increase in 
AAA growth rate in current smokers181. Although highly significant, this effect is 
insufficient to warrant the recommendation of different screening intervals for smokers. 
The UKSAT did measure COPD specifically, and reported that aneurysm rupture risk 
was independently and significantly related to current cigarette smoking. The benefit of 
smoking cessation is demonstrated through a clinical study showing a significant 
difference between ex-smoker and current smoker AAA rupture rates174.  
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1.7.7. Aortic dissection 
Aortic dissection has been related to aneurysm formation. An autopsy study of 84 
consecutive cases observed that 5 patients had associated aneurysms 184. Chronic aortic 
dissections have a tendency to increase in size over time.  All mechanisms weakening 
the media layer of the aorta will lead to higher wall stress with subsequent dilatation, 
aneurysm formation, aortic dissection or rupture. Chronic aortic dissection results in an 
overall weakened affected aortic wall through an instability due to the dissection in the 
first instance, and a weaker outer wall of the false lumen caused by the intima dissecting 
away. Therefore, patients with chronic aortic dissections are at high risk for aneurysm 
formation185.  
 
1.7.8. Atherosclerosis 
The relationship between atherosclerosis and AA remains to be established. Three non-
dominant theories have been suggested. Most aneurysms are associated with 
atherosclerosis186, hence in the past atherosclerosis was advocated as a causative factor, 
and the hypothesis of AAA development secondary to atherosclerosis was supported by 
principles governing arterial remodelling. This theory is opposed by some researchers 
as 3 out of 4 patients with AAA do not demonstrate occlusive vascular disease of the 
aortoiliofemoral segments. Animal studies which have aimed to induce AAA through 
atherogenic diet have not been predictable, and attempts to regress experimental 
atheromas in monkeys have caused aneurysm formation. An alternative theory suggests 
atherosclerosis and AAA formation to be independent entities with shared 
environmental and genetic risk factors. A large Tromso study designed to understand 
the relationship between atherosclerosis and AAA suggested that atherosclerosis and 
AAA develop in parallel, rather than atherosclerosis leading to AAA82. However, this 
study did not consider important confounding factors (for example diabetes), thereby 
not completely refuting the part atherosclerosis play in AAA formation187. Also, 
excessive remodelling as result of atherosclerosis may provide the stimulation causing 
the chronic inflammatory response identified in AAA. Hence, others adopt the view that 
either aortic atherosclerosis or AAA can develop first, and both form part of the 
interactive process that stimulates the other’s development. In fact, Brady and 
colleagues reported a negative association between atherosclerotic burden as measured 
with ankle brachial pressure index (ABPI) and aneurysm growth, suggesting that 
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atherosclerosis has a minimal role in the continuing expansion that characterizes the 
natural history of AAA181. The bulk of the evidence points to AAA disease being a 
systemic disease of the vasculature that may more accurately be described as 
degenerative rather than atherosclerotic. Nevertheless, atherosclerosis plays a role in the 
pathogenesis of AAA as demonstrated by the association of AAA formation and 
progression with atherosclerosis risk factors188, atherosclerotic vascular disease and 
systemic inflammatory markers.  
 
1.8. INTRALUMINAL THROMBUS (ILT) IN AORTIC ANEURYSM  
 
Intraluminal thrombus is found in an estimated 3 out of 4 AAAs189. The presence of an 
ILT has been associated with both expansion and rupture of AA. ILT is described as a 
biologically active laminated structure, containing several layers of fibrin clot, 
underlying a fresh, red haematic luminal layer containing undegraded cross-linked 
fibrin, and an actively fibrinolyzed abluminal layer. Proteolytic and oxidative 
degradation of the arterial wall is caused by this biofunctional unit. The damage occurs 
through fibrin formation, platelet activation, the binding of plasminogen and its 
activators and the entrapment of erythrocytes and neutrophils. This occurs mainly at the 
ILT/circulating blood interface.  
 
Vorp and co-workers demonstrated that ILT attenuated oxygen flow from the lumen to 
the aortic wall, and that a hypoxic environment is more pronounced in aneurysms with 
greater thrombus volume (>4mm). This environment may be responsible for an increase 
in MMP activity in the AA wall, with subsequent weakening, decrease in tensile 
strength and ultimately rupture190. Also, ILT has been shown to be associated with a 
thinner arterial wall, more extensive elastolysis, a lower density of VSMCs in the media 
and a higher level of immuno-inflammation in the adventitia191. This suggests that an 
important part of protease activity originates from the ILT, rather than being directly 
generated within the aneurysm wall191. This work confirms earlier research reporting 
that ILT enhances proteolysis in AAA192. Furthermore, Folkesson et al observed that 
neutrophil gelatinase-associated lipocalin in complex with activated MMP-9 is found in 
AAA walls and thrombi. This relationship may enhance the enzymatic activity 
associated with AAA193. More recently a study observed the differentiation of protease 
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activity within the same AAA wall and its enhancement within the thin thrombus-
covered aneurysm wall194. Experimental models confirm that ILT may contribute to 
AAA progression via its influence on the level of aneurysmal wall  protease activity195. 
Increased inflammatory activity correlated to the abundance of leukocytes has made in 
vivo imaging of superparamagnetic iron oxide (SPIO) uptake at the luminal interface of 
the thrombus with MR imaging a possibility196. 
 
Bleeding into the thrombus as suggested by higher attenuation levels and a ‘crescent 
sign’ is associated with AAA rupture197. Leading on from this work, Polzer and his 
colleagues observed ILT fissures increase the stress in the underlying wall, whereas 
other regions remain unaffected. If ILT fissures reach the wall or involve large parts of 
the ILT, the resulting increase in wall stress could possibly cause AAA rupture198. 
 
Infrarenal aortic thrombus volume is linked with the incidence of cardiovascular events 
and AAA progression199. Some researchers speculate weakening of the AAA wall, 
under the influence of thrombus, might play a more imminent role in AAA expansion 
than wall stress200. This conclusion followed an observation by Speelman and 
colleagues, suggesting that larger thrombus in AAA was associated with a higher AAA 
growth rate, but also with a lower wall stress201. 
 
Nevertheless, wall stress plays a central role in AAA pathobiology and the relationship 
between ILT and wall stress is important. The presence of ILT causes a reduction in the 
peak wall stress. This correlation was mainly observed in smaller aneurysms. Geometric 
configurations of the AAA may influence wall stress in larger aneurysms 202.  
 
1.9. SUMMARY OF AORTIC ANEURYSM PATHOBIOLOGY 
 
Interaction of multiple factors is responsible for the failure of the structural integrity of 
the aneurysm wall, which results in aneurysm formation and progression. Current areas 
of interest include proteolytic degradation of the arterial wall, inflammation and the 
immune response, biomechanical wall stress, and molecular genetics. Insight into the 
pathobiology of AA has led to more targeted imaging methods and treatment trial 
design to investigate various pathobiological mechanisms of AA regression. As it 
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stands, surgical treatment of AA disease continues to be the most effective means of 
addressing the majority of factors involved in AA formation and progression. Non-
invasive in vivo imaging of AA inflammation may offer solutions and yield valuable 
information on the role that inflammation plays in AA pathobiology. This could also 
have potential clinical application such as estimation of growth and rupture risk to help 
with decision about repair. 
  
  Chapter 2 Imaging vessel walls 
CHAPTER 2. IMAGING VESSEL WALLS 
 
2.1. INTRODUCTION 
 
Inflammation is prevalent at several stages of atherosclerotic plaque development 203. 
Inflammation marked by the pathological feature of the infiltration of inflammatory 
cells plays a central role in AA formation and progression. Although the relationship 
between atherosclerosis and AA remains to be established, atherosclerosis plays a role 
in the pathogenesis of AAA as demonstrated by the association of AAA formation and 
expansion with atherosclerosis risk factors, atherosclerotic vascular disease and 
systemic inflammatory markers.  
 
Contemporary imaging techniques can accurately assess vascular wall anatomy and, 
with targeted probes, depict the metabolic processes central in vascular inflammation. 
Technology and probe advances allow for imaging of multiple facets related to the 
vessel wall including expansive ECM remodelling, angiogenesis of the vasa vasorum, 
atherosclerotic  plaque inflammation, and even fibrin deposits on early non-occlusive 
vascular thrombosis204. Expansive or restrictive vascular remodelling is commonly 
found in vascular lesions. Extracellular matrix remodelling by proteolytic degradation 
and cell apoptosis is the predominant characteristic of expansive remodelling204. In 
atherosclerosis, VSMC migration is observed from the adventitia with transformation 
into monocytes or macrophages and subsequent lipid-filled core formation. To allow for 
plaque growth, the ECM adopts an expansive remodelling with inflammation central to 
this process204. It is suggested that this form of remodelling characterizes aneurysm 
formation205. AAAs accumulate inflammatory cells, but usually exhibit much more 
extensive medial damage66.  
 
In atherosclerosis and other vascular diseases, molecular imaging provides insight of the 
disease-specific biological events, enables novel non-invasive strategies for 
individualized risk assessment, and facilitates monitoring of highly targeted thera pies.  
Molecular imaging is a rapidly developing discipline aimed at depicting cellular and 
sub-cellular processes using traditional and novel imaging platforms206.  
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Molecular imaging techniques with ultrasound, MRI, PET and CT individually capture 
only limited aspects of the vast spectrum of pathobiologic events involved in 
atherosclerosis. Therefore, based on their unique advantages and disadvantages, these 
molecular imaging applications may have a complementary, rather than a competitive 
role in depicting the molecular underpinnings of atherosclerosis207. 
 
2.1.1.   Nuclear based molecular application 
In the last few years hybrid PET / CT has become an established clinical imaging 
modality in oncology and clinical cardiology to demonstrate inflammation, ischaemia 
and other disease-specific molecular process mostly reflected through glucose 
metabolism. The development of dedicated fusion imaging systems that combine PET 
imaging or single photon emission computed tomography (SPECT) with either CT or 
MRI have enabled accurate anatomic localization and functional correlation of 
metabolic activity.  
 
The main advantage of nuclear imaging is that sensitivity is many orders of magnitude 
higher than MRI, CT or ultrasound. Compared with MRI and CT, sensitivity for both 
SPECT and PET are within the picomolar range, allowing for functional imaging of 
biomolecular targets with the use of less radiopharmaceutical ligands. PET and SPECT, 
however, have limited spatial resolution (PET 5mm, SPECT 10-15mm) compared to 
MRI and CT which have superior spatial (1mm) and temporal resolution in comparison. 
Combining strengths of the various imaging modalities is  the rationale behind hybrid 
PET/CT and PET/MRI204. Furthermore, FDG PET can provide non-invasive 
quantitative assessment at a functional level indicative of atherosclerotic plaque 
metabolism, hence for example, reflecting the degree of increased vascular glucose 
metabolism, distinguishing it from MRI and echo-based techniques.  
 
Non-invasive quantification of metabolism with both SPECT and PET imaging 
techniques has been extensively described, especially with the 18F-FDG tracer. 
Radiolabelled probes are used to depict activated macrophages within the vessel wall. 
Increased cellular metabolism of glucose forms the principal foundation of 
deoxyglucose imaging.  
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Experimental and clinical studies confirmed that macrophages are the main source of 
FDG uptake in vascular lesions. Newby et al observed that inflammatory cytokines 
trigger MMP induction and subsequent macrophages migration and modulation208. 
Metabolically active macrophages have enhanced glucose uptake and therefore can be 
detected as an increased radioactivity using 18F-FDG as tracer209-211.  
 
Yun et al first reported 18F-FDG uptake in aorta walls in patients with cancer imaged for 
the purpose of staging212, 213. They further described increased FDG uptake in older 
patients. Others demonstrated an association between FDG uptake and cardiovascular 
risk factors214, 215 and also the relationship between vessel FDG uptake with levels of 
inflammatory biomarkers 216. Tahara et al showed that drug therapy can reduce arterial 
metabolic activity217. Similarly, arterial tracer uptake was decreased in patients who 
adhered to dietary and lifestyle changes218. 18F-FDG PET as a vascular imaging tool 
was further validated through clinical histological PET studies which confirmed 
correlation between 18F-FDG radioactivity and carotid plaque metabolic activity210, 219, 
220 and AAA wall inflammation221, 222. 18F-FDG uptake is reproducible223, allowing 
serial non-invasive measurements of the effects of anti-inflammatory drugs on the 
vasculature, including statins217, PPARS (peroxisome proliferator-activated receptor 
agonists)224 and drugs still under development225. Although the association between 
FDG uptake and inflammatory burden in vascular plaque is well described, a recent 
histological PET study suggests that glucose uptake and therefore FDG uptake signal 
may reflect hypoxia-stimulated macrophages rather than mere vascular inflammation226.  
At present, to overcome spatial resolution challenges with PET, 18F-FDG imaging of the 
aorta may be more reliable than functional imaging of smaller arteries, ie carotid or 
coronary arteries227.  
 
Furthermore, radiolabelling of nanoparticles has been attempted in a murine animal 
study with higher 18F-labelled carbohydrate-coated nanoparticles uptake reported in 
TAA 10-12 h after tracer administration228. Nevertheless, high radiation levels and long 
clearance times hinder translation of this tracer into clinical practice.  
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2.1.2. Ultrasound-based molecular imaging applications 
This form of molecular imaging relies on the detection of novel site-targeted modern 
ultrasound contrast agents (UCAs) or other acoustically active particles after ligand-
directed binding to the ROI229. UCAs are gas-filled molecules (or microbubbles) that 
have an outer shell composed of phospholipids, liposomes or other biodegradable 
polymers230. UCAs possess properties that allow ultrasound contrast enhancement so as 
to perform vessel molecular imaging. They are small (1–5μm) with similar rheologic 
behaviour to mature red blood cells231. They are intra-vascular tracers without 
significant retention in the diseased tissue unless selective molecular targeting is 
induced by structural shell changes, or molecular probes are conjugated in the outer 
shell. UCAs tend to undergo volumetric oscillation, providing a greater ability to reflect, 
absorb and re-radiate sound energy232. 
 
Disruptive changes in the modulation of the periadventitial vasculature may have an 
active role in atherosclerosis development and progression233-235. Microbubbles targeted 
to various processes involved in atherosclerosis and thrombosis including endothelium 
adhesion molecules, angiogenesis, thrombus, activated platelets, von Willebrand factor 
and tissue ischaemia have been applied229. Plaque neovascularization has been 
successfully imaged using contrast-enhanced ultrasound and other non-invasive 
imaging such as microscopic three-dimensional (3D) CT and contrast-enhanced 
magnetic resonance (CMR)234. Experimental studies on the use of UCAs with targeted 
probes suggest these microbubbles may depict endothelial activation and immune cell 
retention seen in early atherosclerosis236.  However, low microbubble retention at the 
atherosclerosis site due to high-velocity and high-shear stress, and low specificity of 
selected targets suggest further research development is necessary before human 
translation is attempted236.  
 
The benefit of UCAs for echo-based study is that they remain intravascular, thus 
making molecular imaging of especially the endothelium of large arteries possible. 
However, low acoustic signal and difficulty of detection with routine available 
ultrasound technology and clinical feasibility in vascular imaging is hampered by 
suboptimal accuracy to differentiate between UCAs signal and tissue back ground when 
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using conventional probes. Nevertheless, research is focussing on microbubble design 
and echo-based technology to overcome these issues. 
 
2.1.3.   MRI-based molecular application 
MRI has been successful in demonstrating vascular inflammation by targeting the 
phagocytic avtivity of inflammatory cells. Studies describe the use of ultra-small 
superparamagnetic particles of iron oxide (USPIO), which are circulating iron oxide 
nanoparticles (ferumoxtran-10) that metabolize slowly over 24–36h by the 
reticuloendothelial system. USPIO have a similar molecular size (less than 50nm) to 
oxidized low-density cholesterol (ox-LDL-c), hence their ability to be retained in the 
sub-endothelial space of dysfunctional endothelium237 and their specific affinity for 
scavenger receptors and other outer cell membrane molecules expressed by activated 
macrophages238. USPIO  have nonstoichiometric microcrystalline magnetite cores 
which are mostly coated with dextran or siloxane239. Experimental studies with 
hyperlipidaemic rabbits showed spontaneous uptake of USPIO and superparamagnetic 
iron particles by macrophages in atherosclerotic plaque240, 241. Kooi et al subsequently 
described vascular uptake of USPIO in a clinical study242. This histopathological study 
demonstrated that up to 75% of the ruptured or rupture-prone lesions contained high 
concentrations of USPIO, compared to only 7% uptake by the stable plaques242. 
Furthermore, Trivedi and colleagues described USPIO-enhanced MRI identification of 
carotid plaque inflammation through accumulation of USPIO within plaque 
macrophages in 30 patients with symptomatic disease243. In AAA, a nanoparticle MRI 
study showed a change in decay of transverse magnetization after 36h, suggesting 
potential for use in molecular imaging of vascular walls244. Another study identified a 
subset of patients with distinct USPIO uptake associated with a threefold higher 
aneurysm expansion rate, advocating use as a risk stratification tool245. Visualization of 
USPIO particles within activated macrophages is achieved with T2*-weighted gradient 
echo sequences in which areas of high plaque inflammatory activity are represented by 
signal hypodensity.  
 
Evidence that macrophage activity assessment by MRI is valid in clinical trials is 
robust. High spatial resolution, excellent soft tissue contrast and lack of radiation are 
advantages of this modality. However, the MRI study needs repeating 24-36h after 
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basal image acquisition for comparison of imaging intensities, and this is sometimes 
impractical. Furthermore, there is no correlation between USPIO hypodensity and long-
term clinical outcome, and the long-term safety of using USPIO is questioned. 
 
Other MRI probes focus predominantly on endothelial dysfunction, eg Apo-A1 mimetic 
tracers246 and antibodies targeting oxidized-specific epitopes such as the human IK17 or 
the murine MDA2 and E06247. Platelet activation has also been pursued as potential 
molecular imaging MRI targets248, 249. In order to overcome some technical challenges 
with MRI probe imaging, Caruther studied the colloidal iron oxide nanoparticle 
theranostic platform, a vascular constrained T1- weighted molecular imaging agent, that 
avoided typical magnetic bloom artifacts, allowed for rapid vascular imaging without 
blood pool magnetization interference, and supported targeted drug delivery250. 
 
2.1.4.   Spectral CT molecular imaging 
CT molecular imaging shows promise with evolution of dual-energy and multicoloured 
or spectral CT derived from properties of the photon-processing detector.  Spectral CT 
recognizes the k-edge of metals, which occurs when the attenuation of photons 
interacting with a k-shell electron suddenly increases as a result of photoelectric 
absorption204. Multiple materials can be quantified and differentiated from each other 
simultaneously using spectral imaging, since each material has a specific measurable X-
ray spectrum251. Spectral CT scanners allow for traditional CT image and quantitative k-
edge image data (based on unique spectral footprints of specific elements, for example, 
gold, gadolinium, or bismuth)204. Metal nanocolloid k-edge agents that can localize to 
fibrin fibrils within an intravascular thrombus or other suitable biomarker, have been 
developed204. Localization of hot spots from intraluminal fibrin to the coronary bed are 
made possible through image registration of CT images207. At present its role is seen 
more as an adjunctive imaging tool, with researchers advocating greater efficacy in 
cancer diagnosis and treatment monitoring when combined with PET/CT. Although this 
molecular imaging modality is promising,  technology, image reconstruction and 
display soft ware challenges, as well as the identification of suitable biomarkers for the 
disease in question, all hamper clinical translation 251. 
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2.1.5.   Summary of vascular imaging techniques 
To foresee the clinical application of vascular molecular imaging, technical constraints, 
safety issues and potential clinical impact regarding managing strategies to reduce 
clinical events, needs consideration. Cost-effectiveness, non-toxic low-molecular-
weight probes with an easy accessible imaging platform to some extent elude us. FDG 
vascular imaging currently represents a promising vascular imaging modality; however 
its clinical role remains to be established. Future introduction of 4-D PET and 
appropriate gating may help overcome recognized technical constraints for PET/CT. 
Lack of radiation and therefore benefit in serial monitoring, drives the push for 
widespread clinical use of MRI-based and utrasound-based molecular imaging 
techniques. The emergence of multimodal molecular imaging strategies may prove 
useful, but may not be cost effective. 
 
2.2. HISTORY OF PET /  HYBRID PET/CT 
 
Today, PET is recognized as an established major clinical imaging tool. Nutt et al 
summarized the history, which is marked by significant technological advances that 
shaped modern PET252. Sweet first and later Wrenn et al described the medical use of 
positrons in 1951. The Massachusetts General Hospital study group built the first brain 
probe using two opposing sodium iodide (NaI(Tl)) detectors253.  
 
In 1973, following recognized efforts by scientist and physicians including Hounsfield, 
the first successful PET with a hexatomograph design, known as PETT I, was built at 
Washington University. PETT I lacked proper reconstructed images because it 
employed limited sampling, and did not provide for attenuation correction, but 
nevertheless used a proper filtered Fourier-based image reconstruction algorithm. 
Collaboration with the EG&G ORTEC group saw the development of PETT II with 
automatic rotation of 24 NaI detectors, making a fully sampled data set possible. 
Understanding gained on PET mathematics and physics from studies with PETT I / II 
marked the beginning of modern PET252.  
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In 1974, the Washington study group developed PETT III, with 48 NaI(Tl) detectors, 
for clinical human studies. Shortly thereafter ECAT II, the first commercial PET, was 
produced.  Detectors used in PET are the determining factor in the sensitivity, the image 
resolution and the count rate capability. In the early eighties the introduction of 
bismuth-germanate (BGO) as a PET scintillator was observed. This dense crystal has a 
high effective atomic number, necessary to stop the high energy annihilation photons. 
The first PET III images were captured at Washington University using 11C-glucose, 
15O-water and 13N-ammonia for blood flow, 15O-oxygen for oxygen utilization, and 18F-
fluoride for bone scans. The first synthesized FDG led to the first FDG PET image 
performed in December 1976. 
 
The development in the mid eighties of the ‘electronic generator’ for automated 
production of PET tracers and the validation of the match / mismatch principle for 
determining cardiac viability with 13N- ammonia used for blood flow and FDG for 
glucose metabolism marked other breakthroughs in PET history. The use of PET for 
diagnosis and management of cancer treatment in the nineties helped establish PET as a 
recognized clinical imaging modality. Further advancement of clinical PET came about 
when Siemens and GE joined the PET market.  
 
Introduction of whole-body PET imaging along with the large amount of clinical 
research in cancer, cardiac applications and epilepsy has been crucial in the 
establishment of clinical PET. This resulted in FDA approval of FDG and Health Care 
Financing Administration (HCFA) reimbursement which furthered the evolution of 
modern PET.  
 
The introduction of lutetium oxyorthosilicate (LSO) has further revolutionized PET 
imaging. In comparison it has a slightly greater density, slightly lower effective atomic 
number, and has 5 times more light output than BGO254. LSO provide for up to 2mm 
resolution tomographs that will image the torso in less than half an hour (in systems 
designed for brain studies) or 4-6mm resolution scans in 3-5mins, thereby overcoming 
criticism of the imaging time factor in PET254. 
 
At present the evolution of modern PET is marked by hybrid PET/CT. Improved 
diagnostic accuracy, surgery and radiation therapy planning, by merging the anatomy 
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and functional aspect of disease biology into a single procedure, are amongst several 
benefits.  Fast, low-noise attenuation correction from the CT component also improves 
the PET component. 
 
2.3. PET TRACERS IN RELATION TO ATHEROMA 
 
The locally changed conditions, such as enhanced blood flow, enhanced vascular 
permeability and influx of white blood cells (WBCs), promote the accumulation of 
imaging agents to the site of inflammation255. Several tracers have been studied in the 
evaluation on vascular inflammation, in particular, atherosclerotic plaque. Single photon 
emission computed tomography (SPECT) with in vitro labelled leukocytes has been 
suggested as the ‘gold standard’ for acute inflammation imaging, although the 
sensitivity is suboptimal255-257. 67Ga-citrate, radiolabelled WBCs and indium-111(111In) 
- or technetium-99m(99mTc)-labelled antibodies are used for SPECT assessment of 
inflammation. In chronic inflammation, limited neutrophils migrate to the inflamed site, 
so radiolabelled WBCs are not suitable for chronic inflammation imaging258. This is 
best accomplished with 67Ga-citrate and 18F-FDG tracers which are useful to identify 
both acute and chronic inflammation255, 259; however, neither is an inflammation specific 
imaging agent. In cancer studies, enhanced glucose metabolism is detected with FDG-
PET scanning utilizing the difference in accumulation of 18F-FDG tracers which are 
useful to identify both acute and chronic inflammation between normal and cancerous 
tissues. The reduced specificity of 18F-FDG tracers, in particular the inability to 
discriminate between inflammation and tumour activity, has prompted researchers to 
investigate alternative tracers in cancer research. Other PET tracers, visualizing specific 
molecular pathways in tumours such as proliferation (eg 11C-methionine, 11C-choline, 
18F-fluorothymidine), hypoxia (eg 18F-FMISO) or expression of certain receptors 
(Her2Neu, EGFR) are being used in the evaluation of malignancies. Some of these, as a 
result of individual characteristics, have found use as vascular PET tracers. 
Nevertheless, 18F-FDG PET remains the most widely studied vascular molecular 
imaging technique.  
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2.3.1. 18F-fluorodeoxyglucose (18F-FDG) 
Readily available 18F-FDG is a glucose analogue with a half-life of 110 min which 
decays by b+-emission. The active ingredient is 2-deoxy-2-18F-fluoro-D-glucose which 
accumulates in metabolic active cells and also has been found to be associated with 
neovessel content219, 260, 261, a recognized characteristic of atherosclerosis. It is 
dependent on facilitated glucose transporters (GLUT) and sodium glucose co-
transporters found on the walls of metabolic active cells known to metabolize 
glucose262.  
 
2.3.1.1. How FDG - PET reflects vascular metabolism 
In a recent review Joshi et al263 described the mechanism of  uptake of FDG with PET. 
FDG directly competes with glucose for cell uptake through GLUT transporter proteins, 
hence reflecting metabolic activity at the target site. Subsequently, FDG is 
phosphorylated to FDG-6-phosphate (rendering it resistant to further metabolism) by 
the hexokinase enzyme and thus accumulating within the cell. In theory, glucose-6-
phosphatase can dephosphorylate FDG-6-phoshate, but this enzyme is not greatly 
expressed outside the liver and skeletal muscle cells, and so this effect is considered 
negligible in atherosclerosis. FDG reflect glucose usage of the cell studied, since the 
rates at which glucose and FDG are phosphorylated are proportional to each other264. 
Macrophages play an active role in all stages of vascular inflammation and 
atherosclerotic plaque formation. Macrophages use exogenous glucose for energy. 
Increased radioactivity using 18F-FDG-PET can be used to investigate macrophage 
activity because macrophages express a high basal metabolic rate that is GLUT-
dependent209-211. Histological evidence suggesting a correlation between CD68 as 
marker of macrophage activity and FDG uptake220, 265 further validates this hypothesis. 
Activated macrophages have an enhanced metabolic rate that requires additional uptake 
of glucose. Increased oxidative metabolism with immune cell activation (the 
‘respiratory burst’- phenomenon) is associated with a 20-fold increase in the rate of 
glucose metabolism. Glucose uptake of macrophages is significantly higher than that of 
neighbouring cell types266. Compared with quiescent cells, activated macrophages show 
an increased expression of GLUT type 1 and type 3 receptors, along with hexokinase267-
269. FDG uptake is therefore a function of macrophage density and activation, GLUT 
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transporter expression, hexokinase activity and dephosphorylation, but may also reflect 
hypoxia-stimulated macrophages rather than mere vascular inflammation226. 
 
In vitro studies reported that moderate hyperglycaemia does not affect uptake into 
macrophages270, 271 but that, in humans, reproducibility in those with elevated blood 
glucose levels at the time of FDG imaging is likely to be reduced272. Furthermore, in 
vitro FDG can be taken up into adjacent cell types including endothelial cells and 
lymphocytes273. Further studies are required to demonstrate the relationship between 
18F-FDG vascular uptake and long-term clinical outcomes. 
 
2.3.2. 11C or 18F-choline  
11C- or 18F-choline tracer is metabolized and incorporated into cell membranes in 
tumour cells and macrophages. DeGrado et al274 and Hara275 first developed and 
described fluoromethyl-dimethyl-2-hydroxyethyl-ammonium or 18F- choline (18F-FCH) 
chemistry by the synthesis of no-carrier added 18F-FCH through the intermediate 18F-
fluorobromo-methane (18F-FBM)276, 277. Similarly to 18F-FDG, this choline derivative is 
absorbed into cells by specific transporter molecules, then phosphorylated by choline 
kinase, metabolized to phosphatidylcholine, and later incorporated into the cell 
membrane276, 277. 11C has a short half-life (20.4 mins), which researchers view as a 
logistical limiting imaging factor. An apolipoprotein E -deficient murine study reported 
supremacy of 18F-FCH over 18F-FDG with stronger correlation of fat staining and 
macrophage-positive areas (84% vs. 64%)278. Preliminary data in five patients with a 
total of 31 vessel wall alterations demonstrate the feasibility of 18F-FMCH for in vivo 
imaging of structural vessel wall alteration in humans. Furthermore, in a cohort of male 
cancer patients, a retrospective analysis observed that labelled choline was not taken up 
into normal vascular wall, or purely calcified lesions279.  
 
2.3.3. Radiogallium-labelled compounds  
Generator-produced short-lived radionuclide 68Ga has a half-life of 68 mins and decays 
at 89% by b+-emission (with maximum energy of 1.92 MeV)  and 11 % by electron 
capture to stable zinc (68Zn), and for that reason it can be used for PET imaging280. It is 
an excellent probe for high specific activity labelling of small peptides with fast blood 
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clearance and target localization. The half-life is suitable for labelling many ligands for 
PET imaging and it is short enough to cause minimal radioactive burden for a patient281. 
Six ligands are currently studied in predominantly tumour clinical trials. [68Ga-DOTA, 
Tyr3)]octreotide (68Ga-DOTA-TOC), [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-DOTA-
NOC), [68Ga-DOTA-2-Nal,Tyr3,ThrNH28]octreotide (68Ga-DOTA- Lanreotide) and 
[68Ga-DOTA,Tyr3,Thr8]octreotide(68Ga-DOTATATE) bind differently to subtypes of 
somatostatin receptors (eg somatostatin, vasointestinal peptide receptors, bombesin, 
cholecystokinin, gastrin, and/or substance P), and are studied especially for the imaging 
of neuroendocrine tumours (NETs) and well-differentiated thyroid tumours282-286. 68Ga-
DOTATOC is the most widely used 68Ga-based PET radiopharmaceutical. DOTATOC 
([D]-Phe1-Thy3-octreotide) uptake is observed in lesions with up-regulated 
somatostatin (SMS) receptors. In a recent preliminary clinical study concerning 68Ga-
citrate PET, good visualization of inflammation was obtained at 1.5h after injection287. 
 
2.3.4. Tracers in experimental phase 
Other novel nuclear probes in experimental phase have been suggested for the study of 
vascular inflammation. A promising agent is the translocator protein ⁄ peripheral 
benzodiazepine receptor (TSPO) ligand. TSPO is expressed on macrophages at 20 times 
greater density than VSMCss and TSPO ligands PK11195 and DAA1106 have been 
shown to bind to macrophage-rich regions in human carotid plaque288.  However, TBR 
ratio for TSPO tracers remains unsatisfactory for vascular imaging purposes and a 
recent 4D-PET study concluded that chronic inflammation found in AAA walls was not 
detectable with [11C]-PK11195 and [11C]-d-deprenyl289. Nevertheless, there have been 
recent promising studies in vasculitis290. 
 
 A recent rat study suggested an isomer of glucose, 18F-labelled mannose, as an 
additional avenue for atherosclerotic molecular imaging. In this study 18F-labelled 
mannose and 18F-FDG had comparable uptake. Similar to glucose, mannose is taken up 
by macrophages through glucose transporters, and mannose receptors are expressed on a 
subset of macrophages in high-risk plaques291, 292. 
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Chemotaxis 
Attempts have been made to image the chemokine activity within the vessel wall, since 
chemokines recruit inflammatory cells to the atherosclerotic plaque. Endothelial 
dysfunction and atherosclerotic progression have successfully been visualized using 
99mTc-labelled monocyte chemoattractant protein 1 (MCP-1)293.  
 
Adhesion molecules on endothelial cells or leucocytes 
 Both vascular cell adhesion molecules (VCAM-1) and leucocytes antigen-4 have been 
utilized in atherosclerotic plaque imaging studies294, 295. Kelly et al successfully imaged 
atherosclerotic vessel wall with a conjugated magnetofluorescent nanoparticle VCAM-1 
MRI ligand, since the agent was incorporated by cells expressingVCAM-1294. Clinical 
translation is awaited for (99m)Tc-labelled, anti-VCAM-1 nanobody cAbVCAM1-5 
which allowed visualization of VCAM-1 expression and displayed mouse and human 
cross-reactivity296. 
 
Lipoproteins 
 It is suggested that low-density lipoproteins (LDLs) play a role in early atherosclerosis 
formation and are essential for foam cell generation. Overcoming earlier plaque-to-
background ratio challenges in studying non-oxidized LDL, Ishino et al developed a 
radio-labelled monoclonal antibody targeting LDL receptor 1, to evaluate oxidized 
lipoproteins in the vessel walls297. Other research groups have identified radioiodinated 
AHP7 for selective vascular imaging of oxidized LDL298. 
 
Proteolysis 
 ECM degradation by MMPs leads to progression and complications of atherosclerosis 
and aneurysms. MMPs produced by differentiated macrophages, endothelial cells and 
VSMCs help orchestrate an increased turnover of the ECM, thought to be the reason for 
destabilization of the vulnerable fibrous cap. MMP inhibitors conjugated to 123I, 125I or 
99mTc, has been used for in vivo quantification of proteases in vascular inflammation 
299.  In a murine study, TAA was successfully imaged using a protease-activated 
fluorescent imaging agent, MMPsense 680. Several MMPs can somewhat selectively 
cleave the peptide substrate contained in MMPsense 680300. A gadolinium-based MR 
contrast agent with affinities to MMPs (P947) has also been suggested as a molecular 
imaging tool in elastase-induced AAA301.  
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In a SPECT study, RP782, an 111In-labelled probe targeted to activated MMP, 
demonstrated focal tracer uptake that paralleled CD68 expression in iatrogenic induced 
carotid aneurysms in mice302. Researchers also explored imaging multiple aspects of 
atherosclerosis formation and found a significant correlation between radiolabelled 
MMP and the annexin ligand AA5 (used in apoptosis evaluation) and significantly more 
uptake for both tracers in a high lipid diet rabbit group compared to controls303. 
 
MR detected CAN-35, a collagen-binding protein that preferentially binds to less well-
ordered collagen, has also been utilized in vascular imaging of animal AAA304. 
 
Apoptosis 
Atherosclerosis is characterized to some extent by apoptosis. 99Tc-annexin V has been 
described for quantifying apoptosis305. This tracer targets phosphatidylserine exposed 
by apoptotic and necrotic cells which occurs in SMCs and macrophages in advanced 
lesions as a result of lesion inflammation. Aortic atherosclerosis was imaged by 99 
mannexin A5 with micro SPECT. The quantitative uptake of this tracer correlated with 
histological plaque extent and macrophage content305. Nevertheless, the work of Isobe 
et al and other groups developing apoptosis targets with phosatidylserine-targeted MRI-
contrast agents remains experimental with clinical translation lacking306.    
 
Angiogenesis 
 Evidence suggests neovascularization relates to the inflammatory reaction and 
infiltration of macrophages / foam cells within atherosclerotic plaques307. Alphavbeta3 
integrin is a cell/matrix mediator which also allows for cell signal transduction from low 
affinity to high affinity states. This glycoprotein is abundantly expressed in activated 
endothelial cells.  Radiolabelled alphavbeta3 integrin antagonist for plaque activity 
characterization has been reported. Haubner et al reported 18Fgalacto- RGD (arginine-
glyserine-aspartic), an αvβ3 integrin, a promising potential ligand for plaque 
inflammation visualization308. A recent murine study concluded that since 18Fgalacto- 
RGD uptake was reduced by a lipid-lowering diet intervention, αvβ3 integrin expression 
is a potential for pharmacological therapy response evaluation of plaque309.  
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Although vascular endothelial growth factor (VEGF) receptors have a broad expression 
pattern, researchers have attempted molecular imaging with Cy 5.5-labelled single chain 
VEGF in angiotensin II-induced AAAs with some success310.  
 
Thrombogenicity 
Thrombogenicity is a central feature of plaque vulnerability. Radio-labelled soluble 
glycoprotein VI (a platelet collagen receptor) for assessing thrombogenicity has been 
used to successfully visualize induced thrombogenic carotid vascular lesions in an 
experimental murine study311. 
 
Calcification 
Calcification is believed to represent final stages of the pathobiological process of 
atherosclerosis. 18F-NaF is suggested to detect lesions with active vascular calcification 
and therefore is advocated by Dweck et al as promising for coronary plaque imaging312.    
 
Further work should be undertaken to establish the role of nuclear imaging of various 
pathogenic inflammation factors for non-invasive detection of the vulnerable 
atherosclerotic plaque, diseased or aneurysmal vessels. Time-consuming preparation, 
slow plasma clearance and high cost constraints are barriers for clinical use.  
 
2.4. STANDARDIZED UPTAKE VALUE (SUV) 
 
Several classes of the analysis suitable for PET imaging analysis have been described. 
Nevertheless, the semiquantitative analysis of uptake normalization as a ratio of the 
dose injected per unit weight (SUV) has grown in popularity due to its simplicity and 
convenience of method compared with others. In PET the SUV came to be used as an 
adjunct tool to visual analyisis. The SUV is the average activity per unit volume in the 
region of interest313. To obtain a dimensioned (in mg/mL or m2/mL) result, weight or 
body surface area is used as the time-invariant denominator313. SUV calculation has the 
advantage that dynamic imaging and or blood sampling is not necessary. However, 
imaging must take place at a late time-point, and at the same time-point in sequential 
studies, to meaningfully compare results314. 
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2.5. SUVMAX   , SUVMEAN AND TARGET-TO-BACKGROUND RATIO 
 
Calculating the SUV on the highest image pixel in the region of interest is referred to as 
the SUVmax. Cancer treatment response assessed with FDG PET is often reported using 
SUVmax. Alternatively, region volume can be calculated making use of threshold or 
region growing techniques, and average SUV within the region is presented and referred 
to as SUVmean or multiplied by tumour volume to calculate the total glycolytic volume 
(TGV)315. In order to correct for background activity and false high uptake values a 
target-to-background ratio (TBR) is calculated, by dividing the measured SUV by 
background tissue SUV316.   
SUVmax is more widely used than SUVmean  since it is more reproducible and to a lesser 
extent observer dependent317. Furthermore, Rudd et al suggest that for pharmacological 
therapy trials looking at reducing systemic arterial inflammation, eg statins use, the 
mean TBRmax measurement across a substantial portion of the artery be used, since the 
drug effect is likely to be spread across the arterial bed. However, for evaluating locally 
affecting atherosclerotic plaque therapies (eg vulnerable plaque stent implantation or 
gene therapy), serial TBRmax measurement within the localized disease segment may be 
more accurate223. 
 
2.6. WHOLE-VESSEL SUV 
 
To maximize reproducibility, and as recently described, to assess systemic and 
homogenic inflammatory effect, a whole-vessel analysis of the imaged vessel is 
suggested223, 318, 319. In these studies arterial 18F-FDG uptake in the vessel was quantiﬁed 
by drawing a ROI around the artery to include the vessel wall and content. The average 
and maximum 18F-FDG SUVmax and/or SUVmean was calculated, for each axial level of 
the coregistered transaxial PET/CT images, by adding the values and then dividing by 
the total number of axial images to obtain an average SUVmax and/or SUVmean for the 
whole vessel. TBR was obtained by division of average SUV by an average background 
blood ROI (a minimum of 8 ROI large vein measurements), estimated from the inferior 
or superior vena cava219, 223. Influencing factors on SUV measurement should be 
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considered and appropriate measures taken into account when performing SUV 
analysis. This will be explored in the PET/CT limitations section of this chapter.  
 
2.7. PET/CT LIMITATIONS  
 
In the past, availability of hybrid PET/CT has been reported as a limitation of this 
molecular imaging technique; however, it has become much more widely accessible.  
 
FDG PET/CT has technical limitations. It is suggested there may be a possible 
confounding effect of hyperglycaemia in 18F-FDG vascular uptake, limiting its use in 
diabetics. The clinical significance of this theory has been confirmed by a recent 
vascular PET study showing pre-PET blood glucose levels affect FDG uptake in both 
aortic and carotid walls320. It is thought that competition for cellular transport exit 
glucose, and therefore FDG uptake, may be affected in these patients.  
Furthermore, false positive results and reduced specificity is possible given that glucose 
uptake is a non-specific biomarker of inflammatory activity. Tissues surrounding the 
arteries such as fat and skeletal muscle may display high 18F-FDG metabolic 
accumulation and results could be interpreted erroneously (spillover effects). This could 
be avoided by meticulous measurements of regions of interest, appreciating criteria 
defining precedents such as visual judgment, noise-affected maximum pixel, the 
character of heterogeneity and others321.  
 
The dose of radiation exposure using co-registration imaging modalities is another 
technical limitation to consider. Serial PET imaging may be useful but would be highly 
constrained by radiation dose. The combined radiation exposure from the injected 
radiopharmaceutical and the CT scan during a single PET/CT examination is 
significantly higher than other clinical studies or radiation from natural sources. A 
single 18F-FDG injection can be the source of 7 millisievert (mSv) effective radiation 
and the dose of a limited CTA or CT could range from 3 to 15mSv depending on the 
acquisition protocol, which is comparable to approximately 3y of natural background 
radiation exposure. The cumulative and long-term effects of such levels of radiation are 
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unknown, with more definitive safety information required to consider serial use in 
younger populations.  
 
Measuring vessel wall uptake 18F-FDG is difficult, because of the dimensions involved, 
and the limited spatial resolution of PET. However, the loss of apparent activity (partial 
volume effect) can be overcome to some extent by measuring larger targets more than 
twice the full width at half maximum resolution322. For example, measuring the 
increased diameter of the aorta rather than other studied vessels, eg carotid and coronary 
vessels, reduce partial volume effects. Also the aortic wall expands with aneurysm 
formation323, thus reducing partial volume effects. Accuracy can be improved by 
performing attenuation correction, standardizing reconstruction methods and by partial 
volume correction. 
 
The time of image acquisition also is an important determining factor in SUV 
measurement. The acquisition interval is normally chosen at a time that (dSUV/dt)/SUV 
is not excessive and may vary between research groups. Furthermore it is suggested that 
lean body mass and body surface area rather than weight depict a body volume more 
accurately as denominator for SUV calculation321.   
 
2.8. ETHICAL APPROVAL  
 
Ethical approval was obtained from the University College London Research Alpha 
Ethics committee and regional site specific approval was obtained from the Brighton & 
Mid Sussex Research Ethics committee. All subjects provided written informed 
consent. 
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SECTION II ORIGINAL WORK 
CHAPTER 3. ABDOMINAL AORTIC ANEURYSM METABOLIC ACTIVITY 
DETECTED BY 18F-FLUORODEOXYGLUCOSE (18F-FDG) POSITRON 
EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/CT) 
 
3.1. INTRODUCTION 
 
Abdominal aortic aneurysm (AAA) diameter is an important predictor of risk of 
aneurysm rupture23, 24. However, some aneurysms rupture at a small size23, 324, 325, and 
many large aneurysms grow to a considerable size without rupture. Size therefore is not 
the only determinant for the risk of rupture. Investigators have shown that anatomical 
and dynamic features such as aneurysm shape, aneurysm wall calcification and 
computed wall stress, are also associated with the risk of AAA rupture16, 326. 
 
AAAs are associated with an inflammatory cell infiltrate and enzymatic degradation of 
the vessel wall10, 34, 66. Correlation between risk of rupture and biological markers of 
inflammation has been demonstrated327. Furthermore, immune-mediated processes play 
a role in initiation of AAA disease and rupture22, 106, 328. 18F-FDG accumulates in 
macrophage-rich atherosclerotic plaques and demonstrates that vascular macrophage 
activity can be quantified non-invasively329. Investigators have shown that 18F-FDG 
positron emission tomography (PET) can reliably detect signals  in atherosclerosis214. 
Recently, more researchers showed compelling evidence that this PET signal may be 
related to vascular inflammation, using PET/CT to demonstrate correlation between 
histologically assessed macrophage-dense and/or lymphocyte infiltrate regions and 
FDG uptake221, 222. 
 
An early PET study has been reported to show an increased FDG uptake in only 39% of 
aneurysms34, 222. However, this study assessed larger-size AAAs (mean AAA diameter 
6.3+0.95) with a PET only scanner without the use of CT to correct for density or show 
anatomical detail. The hybrid PET/64-detector CT scanner allows a more reliable 
assessment of increased 18F-FDG uptake in areas of interest on a high resolution CT.  
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The associations between prognosis and the degree of FDG uptake in the wall of small 
AAAs and as assessed by hybrid PET/CT may become increasingly relevant with the 
implementation of aneurysm screening. Preliminary data show that there is increased 
focal uptake of 18F-FDG within the aneurysm wall in patients with large, rapidly 
expanding or symptomatic aneurysms that are prone to rupture 330. However, the role of 
hybrid PET/CT, especially in quantifying the degree of inflammation in patients with 
small AAAs under surveillance, remains to be defined.  
 
Furthermore, the optimum circulation time of 18F- FDG for vascular imaging is 
unknown. In oncology PET studies the 1h time-points are often used331, whereas some 
researchers in cardiovascular imaging advocated performing imaging at 3h after the 
injection of 18F-FDG to maximize the contrast between vascular ROI and 
background210. 
 
The aim of the research in this chapter was to assess the degree of metabolic activity in 
AAAs of patients undergoing surveillance, with 18F-FDG -PET/CT. Assessment is also 
made of possible association between aneurysm tortuosity, calcification, intra-luminal 
thrombus (ILT), expansion rate, and 18F-FDG Uptake. It was hypothesized that the 
detection of inflammation with hybrid PET/CT in the aneurysm walls may help predict 
growth rate and allow evaluation of pharmacological interventions for suppression of 
inflammation in small aneurysms. Further assessment was made of whether there were 
18F-FDG uptake differences in the aortic wall and lumen of the aneurysms at various 
PET imaging times (at 45, 60, 120, and 180min) after an injection of 18F-FDG to 
determine the optimal time to image vascular metabolism using 18F-FDG PET/CT. 
 
3.2. MATERIALS AND METHODS  
 
3.2.1. Patients 
Seventeen patients (sixteen male and one female) with a mean age of 74+5y were 
prospectively studied. All patients had infra-renal AAAs. One of the seventeen patients 
also had common iliac aneurysms. One patient was symptomatic and underwent an 
EVAR (endovascular aneurysm repair). This patient had a large (6.7cm) AAA and 
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presented with associated back pain. Each patient underwent an ultrasound scan 
followed by PET/CT within approximately two weeks of the ultrasound scan. Exclusion 
criteria were the presence of congestive heart failure and/or impaired renal function 
(serum creatinine >1.8mg/dL. The patient characteristics for co-morbidities and oral 
medications are documented in Table 3.1. Study population data for patients with AAAs 
undergoing surveillance, is summarized in Table 3.2.  
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Table 3.1 Patient demographic data 
Characteristics  Surveillance AAAs (n=17) 
Age (mean + SD y) 74 (+5)  
Male M/F  16/1 
Max diameter (mean + SD cm) 5.3 (+0.9) 
Asymptomatic 16 
Symptomatic 1 
Associated back pain 1 
Auto-immune disease 1 
Family history of AAA 0 
Previous major surgery 4 
Risk factors, yes/no  
Smoking 
(previous or current)  
                     9/8 
Hypertension                      8/9 
Hyperlipidaemia                      9/8 
Diabetes Mellitus  2/15 
CAD 2/15 
Prior CVA  0/17 
Prior CABG  1/16 
Malignancy  1/16 
Medications, yes/no  
Anti-platelet  
therapy   
6/11 
B-blockers 3/14 
ACE-inhibitors  6/11 
Statin  10/7 
Laboratory data,   
Elevated CRP  1 
Elevated ESR  3 
 
Abbreviations: CAD, coronary heart disease; PVD, peripheral vascular disease;  
CVA, cerebral vascular accident; CABG, coronary artery bypass grafting; ACE,  
angiotensin converting enzyme; CRP, C-reactive protein; ESR, erythrocyte  
sedimentation rate 
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Table 3.2 Patient characteristics with non-specific AAAs undergoing surveillance 
ID   Diameter 
of AAA 
Diameter 
of AAA 
Increased 
FDG Uptake 
Remarks 
No Sex Age on U/S  on CT (SUVmax>2.5)  
1  M 77 5.3 5.6 YES  
2  M 77 5.7 5.8 YES Prostate cancer 
3  M 74 3.9 4.5 YES  
4 M 75 5.3 5.7 NO Auto-immune 
disease, previous 
major surgery 
5 M 79 5.1 5.6 YES  
6  M 73 4.5 4.5 YES  
7  M 74 4.4 5.3 NO Previous major 
surgery 
8  M 65 - 6.8 YES  
9  M 77 4.7 5.5 YES  
10  M 82 5.4 6.0 YES Previous major 
surgery 
11  M 80 3.1 3.4 NO  
12 
 13 
 14 
 15 
 16 
 17 
M 
M 
M 
M 
M 
F 
68 
68 
64 
  70 
  76 
  71 
4.3 
4.3 
4.3 
6.4 
4.5 
4.3 
4.7 
4.7 
4.9 
6.7 
4.4 
4.7 
YES 
YES 
YES 
YES 
YES 
NO 
Back pain 
 
 
 
 
Previous major 
surgery 
 
3.2.2. Protocol for ultrasound surveillance 
All patients underwent ultrasound scans to measure the size of the aneurysm at intervals 
of 3, 6 or 12 months. All scans were performed in the same unit by experienced 
vascular scientists using standard protocol and equipment.  
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3.2.3. Protocol for FDG-PET/CT  
Patients were instructed to fast for at least 6h prior to the FDG-PET/CT. Images were 
acquired from a single bed position at 45, 60, 120 and 180 minutes after injecting 
200MBq of 18F-FDG using a dedicated combined PET/64-detector CT instrument (GE 
Healthcare Technology, Waukesha, WI). Firstly, an attenuation correction CT was 
performed using 64×3.75mm detectors, a pitch of 1.5 and a 5mm collimation (140kVp 
and 80mA in 0.8s) over the patient’s abdominal aorta. Maintaining the patient position, 
an 18F-FDG PET emission scan was performed and covered an area identical to that 
covered by CT. All acquisitions were carried out in 2D mode (8 min/bed position). 
Transaxial emission images of 3.27mm thickness (pixel size 3.9mm) were reconstructed 
using ordered subsets expectation maximization332 with two iterations and 28 subsets. 
The axial field of view was 148.75mm, resulting in 47 slices per bed position.  
 
3.2.4. Image analysis 
PET/CT images of the infrarenal aorta were reviewed by two combined 
radiologist/nuclear medicine physicians in consensus. One of these readers had a 
specialist interest in cardiothoracic PET/CT (more than 5y).  PET/CT images were 
loaded onto a Xeleris workstation (GE Healthcare Technology, Waukesha, WI). The 
maximum AP aneurysm diameter, tortuosity, symmetry, ILT presence and aneurysmal 
calcification score were determined on the attenuation correction CT. Tortuosity was 
determined through visual assessment. Asymmetry was defined as >1 cm discrepancy in 
major and minor axial diameters. Substantial ILT of the aneurysmal segment was 
defined as ILT with a diameter >10mm on axial plane194. Through visual assessment of 
axial and coronal images, the area of most intense focal AAA wall 18F-FDG uptake was 
identified. Image analysis of AAAs extending into the bifurcation and beyond was 
limited to the aorta. Regions of interest (ROIs) were then drawn over the AAA wall and 
lumen, and the maximum standardized uptake value (SUVmax) and target-to-background 
(TBRmax) blood pool metabolic activity were measured (Figure 3.1). Increased 
18F-FDG 
tracer uptake in AAA was defined as a SUVmax>2.5
333. 
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3.2.5. Calcification quantification 
Calcium scores were calculated for the whole AAA using OsiriX software (Pixmeo, 
Geneva, Switzerland). Arterial calcification was measured from the CT images using a 
threshold for calcium ≥130 Hounsfield units316.  
 
 
Figure 3.1 Axial PET image of an abdominal aortic 
aneurysm with regions of interest (ROI) placed on the 
lumen (roi1) and the wall of the aorta (roi0) 
3.2.6. Statistical analysis 
Data analysis was carried out using the statistical package SPSS® version 15.0 for 
Windows. Data were examined for normality using Kolmogorov-Smirnov testing.  
In a sub-group of fourteen subjects unpaired t-test was used for comparison of FDG 
uptake and the following groups: tortuous and non-tortuous aortas; heavily calcified 
AAAs and non-heavily calcified AAAs, ILT present and ILT absent. The relationship 
between increased FDG uptake and annual expansion was analyzed with Spearman rank 
correlation. The comparison of 18F-FDG measurements across the 4 time-points was 
performed using ANOVA of repeated measures in all 17 participants. A paired 2-tailed 
t-test was used to compare differences between variables obtained at 1h and 3h. A p-
value of less than 0.05 was considered statistically significant and SUV values were 
calculated as mean + standard deviation. 
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3.3. RESULTS 
 
The mean maximum aneurysm diameter in the population studied was 5.3cm 
(SD+0.9cm). Recent AAA expansion within the last year as measured by ultrasound 
was seen in seven patients. Recent annual expansion ≤3mm was observed in three 
patients and four patients had a recent annual growth rate >3mm and <6mm. Two 
patients presented with an expansion >6mm in the last year. There were no 
asymmetrical aneurysms. Five aneurysms were tortuous. The mean aneurysmal 
calcification score was 7973 (SD+6980). Heavily calcified AAA was defined as AAA 
with a calcification score > 10000. This threshold was at approximately the 75th 
percentile. Four aneurysms were heavily calcified with scores >10 000. Intra-luminal 
thrombus >10mm194 in diameter was seen in the aneurysmal sac of six patients.  
 
3.3.1. Relationship between clinical characteristics and 18F-FDG Uptake  
Thirteen aneurysms showed an increased FDG uptake (SUVmax>2.5). No significant 
correlation was found between the degree of FDG uptake and recent AAA growth rate 
(Spearman’s correlation coefficient; r=0.18; p=0.60). Furthermore no association was 
observed between cross-sectional infra-renal AAA diameter and SUVmax (Spearman’s 
correlation coefficient; r= -0.006; p=0.96) (Figure 3.2). PET/CT revealed no other 
clinical findings. Furthermore, only four patients in our study revealed a SUVmax < 2.5.  
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Figure 3.2 Scatter plot of maximum standard uptake 
values (SUVmax) of 
18F-fluorodeoxyglucose (18F-
FDG) illustrating no association between AAA size 
and FDG uptake (rs=-0.006; p=0.96) 
3.3.2. Relationship between anatomical characteristics and 18F-FDG Uptake 
 There was no significant difference in FDG uptake between tortuous and non-tortuous 
aortas (unpaired t test; t(12)=0.72, CI=-1.19-2.37, p=0.48), or between heavily calcified 
aneurysms and non-heavily calcified aneurysms; (unpaired t test; t(12) =-1.48, CI=-
2.65-0.51, p=0.17). This investigation failed to demonstrate a significant difference in 
SUVmax   between AAAs with or without the presence of ILT (unpaired t test; t 
(12)=0.51, CI=-1.26 – 2.03, p=0.62). 
 
3.3.3. Optimum circulation time for 18F-FDG 
Findings of the assessment of optimum circulation time for 18F-FDG uptake are 
summarized in Table 3.3. 
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Table 3.3 Data for SUVmax of aortic wall, aortic lumen, and 
TBRmax at each time-point after injection of 
18F-FDG 
Area Time (min) 
Wall SUVmax 45 60 120 180 
 Mean 2.08 2.15 1.62 1.99 
 % change 0 +3% −22% −4% 
 SD 0.44 0.46 0.26 0.745 
 SE 0.11 0.11 0.62 0.18 
Lumen SUVmax     
 Mean 2.3 2.4* 1.74 1.7* 
 % change 0 +4% −24% −26% 
 SD 0.4 0.44 0.41 0.4 
 SE 0.1 0.11 0.1 0.1 
TBRmax     
 Mean 0.91 0.91 0.96 1.01 
 % change 0 0 +6% +11% 
 
SD – Standard deviation; SE – Standard error; TBRmax – 
Maximum target-to-background ratio  
*Significant difference in SUVmax in lumen  
at 60 and 180 min (paired t test, p < 0.001) was observed 
 
Aortic wall SUVmax and lumen SUVmax were significantly different with time (repeated 
measures ANOVA, p=0.02 and p=0.001, respectively).  There was no significant 
difference in TBRmax with time (repeated measures ANOVA, p=0.206). Furthermore, no 
significant difference between SUVmax at 60 and 180 min in the aortic wall was 
observed (paired t test, p=0.367); however, there was a significant difference in SUVmax 
in the lumen at 60 and 180min (paired t test, p=0.001). There was no significant 
difference in TBRmax between 60 and 180min (paired t test, p=0.131). 
 
3.4. DISCUSSION 
 
The use of FDG-PET/CT in vivo has previously been described in patients with 
symptomatic and/or larger-sized AAAs330. In this chapter we evaluate for the first time 
the role of hybrid FDG-PET/CT to detect increased inhomogeneous metabolic activity 
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and its association with anatomical features, in predominantly small AAAs, in patients 
undergoing routine surveillance. 
 
This study shows that the majority (n=13) of patients demonstrated an increased FDG 
uptake (SUVmax>2.5) in the aneurysm wall. Inflammatory processes may, therefore, be 
present to some extent in most aneurysms. In contrast, a PET study by Sakalihasan N et 
al reported increased FDG uptake in only 39% of their study population34.  However, in 
Van Damme and Sakalishan’s study, their definition of PET positivity was not clearly 
defined, and positive PET findings may have been judged solely on appearance of ‘hot 
spots’. Also patients with larger-size aneurysms were studied (mean AAA diameter 
6.3+0.95) as compared to our investigation of smaller aneurysms (mean AAA diameter 
5.3+0.9 cm). Furthermore, the study performed PET independent from CT scan, 
whereas in our study hybrid PET/CT was used. The benefit of hybrid PET/CT over 
independent imaging modalities is described in the literature334. Combined PET/CT, as 
used in our study, eliminates the positional discrepancies and some of the challenges 
brought on by different test timings when interpreting investigation findings. Improved 
test sensitivity due to technology and technique advances may partly explain the global 
higher SUVmax   in our study. Factors influencing AAA wall inflammatory processes 
require further investigation and prospective studies are necessary to establish the role 
of PET/CT in quantitative assessment of inflammation in AAAs and the clinical 
significance thereof.  
 
Rapid expansion in large aneurysms and its association with increased FDG uptake  was 
reported in a preliminary study330. In comparison, our study revealed a weak correlation 
between recent AAA expansion (within the last year) and FDG uptake, which was not 
statistically significant (p= 0.16). Irregular and unpredictable progression of small 
AAAs39 and small patient numbers (n=14) could explain our results. The relationship 
between FDG uptake and AAA growth rate and risk of rupture in AAA under 
surveillance remains unanswered. Furthermore, correlating focal increase in FDG 
uptake with histological findings from the rupture site may prove to be impossible.  
 
Maximal AAA diameter measured with CT is significantly and consistently larger than 
maximal AAA diameter measured with ultrasound88, 336. This explains the discrepancy 
seen in some of the maximal AAA measurements between ultrasound and CT displayed 
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in our study. Our work confirmed similar findings by Reeps et al in that no relationship 
was found between cross-sectional infra-renal AAA diameter and increased aortic wall 
glucose metabolism222 (Figure 3.2).  A recent study suggests aneurysm wall stress to be 
more predictive of rupture risk than AAA diameter326. Further research is required to 
assess the relationship between increased glucose metabolism and increased AAA wall 
stress.  
 
Ruptured AAAs tend to be less tortuous, yet have greater cross-sectional diameter 
asymmetry16. Interestingly, our patient population showed anatomical characteristics of 
aneurysms associated with less risk of rupture. Tortuosity was demonstrated in five 
patients and no asymmetry detected, yet most study patients had an increased FDG 
uptake. PET/CT did not reveal a significant difference in FDG uptake between tortuous 
and non-tortuous AAAs (p=0.48). It is reported that the presence of calcification 
increases AAA peak wall stress, suggesting that calcification decreases the 
biomechanical stability of AAAs40. Another study showed that the 18F-FDG uptake sites 
were mostly distinct from the calcification sites215. There was no correlation detected 
between increased FDG uptake and degree of calcification found (p=0.17). We and 
others219 suggest that the clinical significance of the relationship between vascular-wall 
18F-FDG uptake and CT calcifications needs to be assessed by further prospective 
studies with long-term follow up. The role of intra-luminal thrombus and its influence 
on the AAA wall remains to be established. Although, studies suggest ILT reduces 
aneurysmal wall pressures40, 102, pathological studies show formation and accumulation 
of inflammatory cells in thrombus-lined vessels that may perturb the structural integrity 
and stability of the vessel wall, and thereby increase the risk for aneurysm rupture191. 
No significant difference in increased FDG uptake between AAAs associated with or 
without ILT was observed (p=0.62). Nevertheless, these results should be interpreted 
with caution in a small preliminary study population in which type II statistical errors 
cannot be excluded.  
 
There is a need for uniformity of vascular PET/CT imaging methodology to enable 
comparison and collaboration between institutions. The significant difference observed 
between 18F- FDG uptake at 1 and 3h post tracer injection has implications for patient 
throughput and to allow for a more acceptable patient journey. However, a recent 
vascular PET study has suggested an optimum FDG circulation time for vascular 
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PET/CT of about 2.5h, after tertile analyses revealed this 18F-FDG circulation time has a 
favourable association between arterial and blood-pool FDG uptake320. At the time of 
the current study there was no uniformity in vascular PET/CT imaging time. Therefore, 
in this study 18F-FDG uptake on PET/CT was measured at 3h to improve the 
reproducibility of the technique.  
 
Despite the improved reliability of integrated 64 slice PET/CT there are some 
limitations that need to be addressed. The partial volume effect observed in small thin 
targets such as the AAA wall may affect the accuracy of FDG PET/CT. Results could 
be more accurate with the implementation of volume effect correction. Furthermore, 
differences in activity or volume could influence the accuracy of signal interpretation.    
 
In an immunohistochemical study, Mochizuki et al reported that the expression of 
glucose transporter protein (GLUTs) was detected in inflammatory tissue, which 
showed 14C-FDG uptake higher than that of normal control muscle337. Therefore, the 
presence of inflammation was suggested by FDG accumulation. The findings in this 
study offer in vivo evidence that AAA show increased glucose metabolism, mediated by 
the Glut-1 transporter. 18F-FDG PET/CT identifies metabolic activity in abdominal 
aortic aneurysms, whether they have or have not the anatomical characteristics of 
aneurysms at risk of rupture. Increased glucose metabolic activity in the aneurysmal 
wall as detected by PET/CT may be present in most AAAs. Although preliminary data 
showed PET/CT to be promising in identification of a varying degree of glucose 
metabolic activity in AAAs, its clinical role in predicting growth rate and rupture risk in 
patients with small AAAs undergoing surveillance remains to be defined by larger 
studies. The possible benefit of anti-inflammatory therapeutic approaches in patients 
with AAA under surveillance is a prospect that remains to be demonstrated. Hybrid 
PET/CT may be a valuable assessment technique in identifying the role that 
inflammation or metabolism plays in AAA disease. 
 
Summary of findings: 
 Increased 18F-FDG uptake (SUVmax>2.5) was observed in 13/17 AAAs. 
 Recent AAA expansion did not correlate with 18F-FDG uptake. 
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 There was no significant difference in 18F-FDG uptake between tortuous compared to 
non-tortuous aortas; heavily calcified versus non-heavily calcified; and AAAs with or 
without ILT.  
 There was no significant advantage in imaging at 3h over 1h after 18F-FDG injection. 
 
 
Figure 3.3 Axial (a) Unenhanced CT, (b) PET, and (c) 
PET/CT fusion of an AAA demonstrating 18F-FDG 
circulating in the arterial and venous lumens and no 
uptake in the wall of the aorta 
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Figure 3.4 Axial (a) Unenhanced CT, (b) PET, and (c) 
PET/CT fusion of an AAA showing uptake in the lumen 
and increased uptake in the wall of the aorta 
 
The relationship between 18F-FDG PET and AAA expansion could be further 
investigated to provide insight into AAA biology. The next chapter in this thesis 
investigates the potential correlation between AAA wall inflammation and future 
aneurysm growth to gain insight in FDG PET/CT as a potential risk stratification 
method for small AAA.  
  Chapter 4 AAA metabolic activity and aneurysm expansion 
CHAPTER 4. RELATIONSHIP BETWEEN 18F-FDG AORTIC ANEURYSM UPTAKE ON 
PET/CT AND ANEURYSM GROWTH RATE 
 
4.1. INTRODUCTION 
 
Screening programmes for aortic aneurysms are being introduced in North America and 
Europe. The increase in surveillance is creating demand for further risk stratification 
whilst intensifying the need to develop strategies for retarding growth rate in small 
aneurysms (maximum diameter between 3.0 and 5.5cm)338. Investigators advocate a bi-
modal growth pattern for AAA, with a recent finding of a significant association 
between annual AAA growth rate of at least 2mm and AAA-related events21. A 
watchful waiting approach is suggested for AAAs with lower growth rates as a result of 
lipid-lowering drug treatment or as determined by initial AAA diameter 
measurements33.  It would be important to detect sub-groups at risk of aortic expansion 
and to identify methods of measuring response to therapy in these patients73, 339-341. It 
would also be attractive to develop non-invasive in vivo imaging techniques to detect 
and quantify aneurysm inflammation and thereby possibly growth rate.  
 
The use of fluorodeoxyglucose positron emission tomography ( 18F-FDG PET) as a 
potential biomarker in vascular disease is becoming more widespread73, 111, 210, 215, 217, 219, 
339-344. Although prospective 18F-FDG PET data have demonstrated instability of plaque 
in the carotid arteries210, 219 and in the assessment of arteritis318, 345, it has not been 
applied to risk- stratification in AAA expansion. A small study with standalone 18F-
FDG PET showed equivocal findings34. 18F-FDG hybrid PET/CT had not been used 
until recently, but recent histologically validated studies showed that increased aortic 
18F-FDG uptake on PET/CT predicts the degree of wall inflammation221, 222. 
 
Currently there are clinical management dilemmas in the treatment of patients with 
small aneurysms and patients with large aneurysms with co-morbidity rendering them at 
high surgical risk. Both these types of patients are increasingly being identified with 
newly implemented AA screening programmes346, thus exacerbating the dilemma. 
There is need to risk-stratify these patients and thus it is important to explore possible 
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roles of non-invasive imaging techniques such as 18F-FDG PET/CT.  We therefore 
prospectively studied the relationship between aortic wall 18F-FDG uptake and 
expansion rate, in patients with AAA, undergoing routine surveillance with ultrasound 
size measurements.  
 
4.2. MATERIAL AND METHODS 
 
4.2.1. Patients 
During a 12-month period, patients presenting to University College Hospital, London 
or Royal Sussex County Hospital, Brighton, with AAA undergoing surveillance were 
invited to participate in this prospective 18F-FDG-PET/CT study.  In that year, 34 
consecutive patients [31 men, 3 women, median age 75y (IQR 71 - 78)] were recruited 
for 18F-FDG-PET/CT. The patient clinical profile is presented in Table 4.1. Nine 
patients were lost to follow up at 12 months (deceased n=2, withdrew from study n=1, 
failed to attend ultrasound scan n=5, emergency AAA repair n=1), leaving 25 patients 
for analysis. 
 
Table 4.1 Summary of the medical details of the patient population 
History or Symptoms  Number of patients (n=25) 
Back or abdominal pain present 3 
Ischaemic heart disease 7 
Raised lipids 19 
Diabetes 3 
Hypertension 19 
Current or previous smoker 16 
 
 
4.2.2. Duplex ultrasound image acquisition 
Study patients underwent abdominal ultrasound at the time of PET/CT examination and 
subsequently routine ultrasound scan measurements at 6 and 12 months post PET/CT. 
Specialist vascular scientists, with greater than three years’ experience, performed the 
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surveillance ultrasound scans (Philips, HDI 5000, C5-2, Curved Linear Probe). In 
keeping with other researchers347, maximal anteroposterior (AP) external aortic wall 
diameter was recorded on each occasion. To correct for baseline aneurysm size the 
authors calculated expansion at 12 months divided by aneurysm size at time of PET/CT 
scan.  
 
4.2.3. PET/CT image acquisition 
All patients were fasted for 6h prior to scans, and images were acquired 3h217, 219, 223, 348 
after injecting 200MBq of 18F-FDG using a dedicated combined PET/64-detector CT 
instrument (GE Healthcare Technology, Waukesha, WI). CT was performed using 
64×3.75 mm detectors, a pitch of 1.5 and 5mm collimation (140kVp and 80mA in 0.8s) 
over the patient’s abdominal aorta.  Maintaining the patient position, an 18F-FDG PET 
emission scan was performed and covered an area identical to that covered by CT.  All 
acquisitions were in 2D mode (8 min/bed position).  Transaxial emission images of 
3.27mm thickness (pixel size 3.9mm) were reconstructed using ordered subsets 
expectation maximization332 with 2 iterations and 28 subsets.  The z-axial field of view 
was 148.75mm, resulting in 47 slices per bed position. Axial fused PET/CT (a) and PET 
(b) images of an AAA showing 18F-FDG uptake and minimal 18F-FDG uptake in the 
wall of the aorta are shown in Figure 4.1 and Figure 4.2, respectively. 
 
 
Figure 4.1 Axial fused PET/CT (a) and PET (b) images of 
an AAA showing 18F-FDG uptake in the wall of the aorta 
(whole vessel SUVmax=3.35; whole vessel TBRmax=1.60) 
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Figure 4.2 Axial fused PET/CT (a) and PET (b) images of 
an AAA showing minimal 18F-FDG uptake in the wall of 
the aorta 
 
4.2.4. Image analysis 
PET/CT images were reviewed both by a dual accredited radiologist/nuclear medicine 
physician with a special interest in cardiovascular imaging and with greater than three 
years’ experience of measuring vascular 18F-FDG uptake, and by a surgeon with a 
special interest in vascular imaging, supervised by a dual accredited radiologist/nuclear 
medicine physician. (PET/CT images were loaded onto a Xeleris workstation (GE 
Healthcare Technology, Waukesha, WI). To maximize reproducibility and as recently 
described223, 318, 343, we performed a whole vessel analysis of the imaged abdominal 
aorta349. Through visual assessment of axial and coronal planes of the imaged aorta, 
measurements were commenced on axial images from distal to the neck of the AAA and 
proximal to distal descending aorta where vessel diameter normalizes to include the 
whole volume of the aneurysm. AAAs extending into the bifurcation were measured up 
to the level of the bifurcation of the aorta.A region of interest (ROI) was placed to 
include the aneurysm wall and content. The maximum 18F-FDG uptake (SUVmax) of the 
whole AAA was calculated subsequently for each axial level and the values were then 
summed and divided by the total number of axial images to obtain an average SUVmax 
for the whole AAA. TBRmax was calculated by division of average SUVmax by an 
average blood ROI (at least 8 venous ROI measurements), estimated from the inferior 
vena cava316. In addition, for each individual AAA we identified the site of maximum 
aortic wall18F- FDG uptake. At this site we measured the SUV, yielding in each patient a 
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single site SUVmax, as previously described
222, 348. The SUV is the decay-corrected 
tissue concentration of 18F-FDG (in kBq/g), adjusted for injected 18F-FDG dose and 
body weight (in kBq/g)350. The interobserver agreement between the two readers was 
recorded.  
 
4.2.5. Statistical analysis  
Following tests for normality, non-parametric statistical tests were performed and 
median values thus presented.  Mann-Whitney U tests were used to compare aortic wall 
18F-FDG uptake values and clinical factors.  Correlations were performed using 
Spearman Rank Correlation.  Statistical tests were performed with SPSS (Version 16.0).  
Statistical significance was set at 5%. 
 
4.3. RESULTS 
 
4.3.1. Aortic 18F-FDG uptake and ultrasound measurements 
The median maximal whole abdominal aortic wall 18FDG uptake (SUVmax) was 1.70 
(IQR 1.45-2.08). The median single site SUVmax was 2.17 (IQR 1.89-2.73). The median 
whole vessel TBRmax was 1.15 (IQR 1.00-1.40). The median maximal aortic AP 
diameter was 50.0 (IQR 40.4-53.5)mm. The median maximal aortic AP diameter 12 
months following the PET/CT imaging was 53.0 (IQR 46.0-58.5)mm. The median 
aneurysm expansion at 12 months was 2.0 (IQR 0.05-5.0)mm (range 0-9)mm (Figure 
4.3).  
 
The correlation (r) between whole-vessel 18F-FDG SUVmax and ultrasound expansion at 
one year was - 0.501 (p=0.011), (Figure 4.4). The correlation between the single site 
SUVmax and aneurysm growth after 12 months (r =- 0.279 p=0.176).  No significant 
relationship between whole vessel TBRmax and annual expansion was found (r=0.031, 
p=0.882). Male patients had a median whole abdominal aortic wall SUVmax of 1.70 
(IQR 1.45-1.95) whilst female patients had a median whole vessel SUVmax of 1.47 (IQR 
1.45-1.50) (p=0.267). There was no correlation between patient age and whole 
abdominal aortic wall SUVmax or TBRmax observed (r =- 0.031; p=0.882; 0.02, 
p=0.925).  There was no association between whole abdominal aortic wall SUVmax and 
 97 
 
 Chapter 4 AAA metabolic activity and aneurysm expansion 
initial aneurysm size (r=0.032, p=0.878). There was no significant difference between 
whole vessel TBRmax in aneurysms with greater or less than 5mm expansion at 12 
months (p=0.852). 
 
 
Figure 4.3 Bar chart showing the consecutive series 
of individual subject’s AA expansion over 12 months  
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Figure 4.4 Scatter plot showing ranked correlation 
between 18F-FDG uptake on baseline study against 
expansion at 12 months (rs=- 0.501; p=0.011) 
 
4.3.2. PET interobserver agreement  
The mean difference between the two observers’ measurements was 0.187 [95% CI: 
1.608 – 1.792]. 
 
4.4. DISCUSSION 
 
The findings from this chapter on 25 AAA patients suggest an inverse trend between 
18F-FDG uptake on PET and future AAA expansion.  
 
There are multiple possible risk factors that have been identified for ruptured AA 
including age, gender, smoking and genetic factors73, 339-341. Other than aneurysm size, 
other anatomical risk factors on imaging have been suggested to play a role in aneurysm 
growth and potential rupture, for example aortic calcification, aneurysm shape and 
computed wall stress16. Despite the recognition of many risk factors, their utility on 
risk-stratification or current screening programmes remains uncertain.  Nonetheless 
there are now increasingly refined guidelines on screening aortic aneurysms 351.  These 
recognize roles for ultrasound in screening. The findings in this chapter suggest that 
there could be a possible role for PET/CT in risk-stratification of patients with 
aneurysms detected during screening, since aortic 18F-FDG uptake was inversely related 
to future aneurysm expansion.   
 
There are reports that increased metabolic activity as detected by FDG-PET/CT may be 
present in asymptomatic AAAs352, 353. However, there is difficulty when interpreting 
such studies as the data is derived solely at one time-point and therefore reflects 
aneurysm wall metabolism at a single moment in time.  In contrast, the biology of AA 
formation is assumed to evolve over many years. 18F-FDG PET studies showing 
longitudinal data are limited. In one AA study a follow-up component was provided34 
but the findings were difficult to interpret because follow-up was provided in only 6/26 
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patients and the follow-up period non-uniformly. In our study with homogenous 
longitudinal data in 25 patients over 12 months, we show that whole AAA 18F-FDG 
uptake is less in aneurysms that expand more with time.  These finding should be seen 
in the light of histologically validated evidence that 18F-FDG uptake in humans is 
related to the degree of inflammatory markers and infiltrate in AAs222 and in other 
arteries329. It could be argued that an initial inflammatory phase is followed by a 
dilatation phase.  Such a hypothesis and our findings are consistent with emerging 
cellular evidence that aneurysm dilatation develops after initial inflammatory 
processes168, 169, 354 and calcification possibly represents a late burn-out stage of 
atherosclerosis316. Interestingly, some PET imaging studies have confirmed that 
increased FDG uptake in arteries may not persist with time 354.  
 
Current medical therapies (statins, ace inhibitors and beta blockers) for patients with 
aortic aneurysms have not been proven to be effective in influencing outcome 340 and 
new targeted therapies are required. The potential role of 18F-FDG -PET/CT in 
developing targeted metabolic treatment should be considered.  There are many 
examples of monitoring cancer metabolic response to therapy with 18F-FDG-PET/CT355, 
356.  However, such models are not confined to oncology and there is increasing 
evidence that PET/CT can be used successfully to monitor treatment in atheroma 217, 219, 
342. Since these early studies have shown promise, larger scale clinical trials are being 
performed and some of these have now been completed225. 
 
There are study limitations and technical considerations when interpreting our findings.  
Our population size is larger than most arterial PET studies performed at the time of the 
current investigation. Our population size was similar to 2 recent longitudinal PET 
arterial dissection studies357, 358 and benefited from a longer follow-up period. 
Nonetheless more data would be needed to confirm our findings. Serial PET imaging 
may be useful but would be constrained by radiation exposure. This is reflected in the 
literature with only one case study reporting a correlation between aneurysm wall 
glucose metabolism and mechanical instability and inflammatory changes with increase 
in aneurysm size over time107.  
 
We performed whole vessel SUV and TBR analysis in keeping with current 
recommendations223, 319, 359. Whole vessel SUV and TBR has been shown to maximize 
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reproducibility and has been advocated for plaque treatment response studies223, 359, 360. 
Furthermore, by averaging SUV measurements to obtain a whole volume tracer uptake 
value, erronous outlier measurements are to some extent being corrected for. In keeping 
with current concepts describing AAA as a systemic disease of the vasculature9, whole 
vessel SUV and TBR measurements may more accurately reflect AAA metabolic 
activity and should be considered in AAA risk stratification and treatment response 
studies. A limitation of this approach is that the site of maximal dilatation on ultrasound 
or site of aneurysm development may not be specifically evaluated on PET. However, 
we also observed a negative trend between single site SUVmax and annual AAA 
expansion, albeit not reaching statistical significance. We did not present mean SUV 
measurements since we were measuring large dilated vessels in which the PET signal 
will be diluted by a large blood pool component. For this reason also, it may not be 
appropriate to make target-to-background activity measurements.  Other forms of AA 
have been studied including inflammatory361 and acute aortic syndromes333. These 
forms so far are generally believed to be a separate pathology and were excluded from 
this investigation, although there may be an overlap in disease pathogenesis. 
Furthermore, since the magnitude of wall stress is related to AAA diameter362 and 
possibly metabolic activity196, the role of inflammation may be less in smaller 
aneurysms.  
 
Mechanisms resulting in weakening of media layers of the aorta ultimately  cause higher 
wall stress, which can induce aortic dilatation and lead to intramural haemorrhage,  
aortic dissection, or rupture363. This thesis investigated the relationship between FDG 
uptake in AAA and growth rate. Previous studies have documented FDG uptake in 
AAA at single time- points34, 222, 330, 352. Sakalihasan et al reported increase FDG uptake 
in a proportion of AAA patients (10/26)34; Truijers et al in comparison to non-
aneurysmal aortas353; and Reeps et al in comparison to asymptomatic AAA222. In one 
series of 5 patients, sites of focal FDG uptake led to focal expansion or dissection in 
time in 3 patients351. Whether FDG uptake persists in AAA is unknown, but is unlikely 
given the waxing and waning uptake demonstrated by Menezes et al348, which is 
consistent with periods of rapid growth and quiescence in the natural history of AAA 364. 
In common with other studies of the expansion of AAAs, there are methodological 
challenges: the change in aortic diameter over time is small and the measurement of 
aortic diameter using ultrasound (and to a lesser extent CT) has an error margin of 2 to 
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3mm which is larger than the annual expansion of many small AAAs364. Therefore 
larger longitudinal studies with longer follow-up are needed to clarify the role in risk 
prediction with FDG-PET in the surveillance of AAA.  
 
In conclusion, the findings in this chapter suggest that there is an inverse trend between 
FDG uptake on PET and future AAA expansion. Aortic aneurysms with lower 
metabolic activity may therefore be more likely to expand.  
 
Summary of findings: 
 18F-FDG SUVmax correlated inversely with future AAA expansion at one year.  
 
Combining imaging techniques with 18F-FDG PET/CT may prove more effective in 
identifying patients at risk of significant expansion and therefore AAA-related events. 
The following chapter investigates AAA CT signal heterogeneity and its relationship 
with 18F-FDG uptake on PET/CT and prospective aneurysm expansion in patients with 
small AAA to explore risk-stratification in AAA progression.  
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CHAPTER 5. INVESTIGATING AA CT TEXTURAL ANALYSIS AND 18F-FDG 
UPTAKE ON PET/CT AND FUTURE GROWTH RATE 
 
5.1. INTRODUCTION  
 
Other than measuring AAA anteroposterior (AP) diameter on CT or ultrasound, other 
imaging methods have been used to improve risk-stratification in AAA. An area of 
interest has been the use of 18F-FDG PET/CT, which has shown promise in semi-
quantitative assessment of metabolic activity in AAA walls222, the extent of which 
might predict future expansion365. Macrophages play an active role in all stages of 
vascular inflammation and atherosclerotic plaque formation. Increased radioactivity 
using 18F-FDG-PET can be used to assess macrophage activity because these cells have 
a high basal metabolic rate that is GLUT (glucose transporter) dependent209-211.  
 
Up until now the CT component of the PET/CT scan has been used mainly for PET co-
registration. CT can be exploited to quantify signal heterogeneity of tissues via textural 
analysis by assessing image grey-level distribution and degree of coarseness. In 
vascular disease, CT textural analysis (CTTA) has been used to investigate  intraluminal 
thrombus in AAA after intervention366 and carotid atherosclerosis367. An approach to 
quantify CT signal heterogeneity via CTTA is to use the filtration-histogram method to 
enhance features at fine, medium and coarse texture-scales. Histogram characteristics 
such as the standard deviation (SD) that relates the degree of variation from the mean 
pixel value, and kurtosis (K) that reflects the pointedness of the histogram, could then 
be quantified.  
 
Furthermore, in oncology, CTTA parameters (SD and K) have been used to evaluate 
heterogeneity of various tumour types, with histological validation of the signals 
(representing hypoxia and neovascularization)368, 369, that have been associated with 
overall and progression-free survival in lymphoma, oesophageal and colorectal 
cancers369-371. The biological basis for such findings is unclear, but may reflect areas of 
hypoxia/metabolic mismatch. AAA is associated with atherosclerosis186  and is 
characterized by structural enzymatic degradation of elastic media, inflammatory 
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infiltrate and neovascularisation58. Increased CT signal heterogeneity of vasculature 
may suggest structural changes with increased vascularity372-374.    
 
In this chapter we investigate small AAA using CTTA that attempts to link these 
parameters with prospective aneurysm growth. For these reasons we assessed the 
potential role of CTTA as a risk-stratification tool for expansion in patients with small 
AAAs under surveillance. We also assessed correlation of CT features of heterogeneity 
with the FDG signal derived from PET.  
 
5.2. MATERIALS AND METHODS 
 
5.2.1. Patients 
During the period from February 2008 to June 2011, patients enrolled under AAA 
surveillance at one of our institutions (University College Hospital, London or Royal 
Sussex County Hospital, Brighton) were invited to participate in this prospective CTTA 
and 18F-FDG-PET/CT study.  Fifty consecutive patients (44 men, 6 women, median age 
75y, range 56-85y) with small aortic aneurysms (median diameter 48.5mm, IQR 43.0-
53.0) under routine surveillance were recruited for CTTA and 18F-FDG-PET/CT. All 
patients had an asymptomatic infrarenal AAA. One patient also had an iliac aneurysm. 
Patients with thoracic, inflammatory and or symptomatic AAA were excluded. The 
baseline demographics are presented in Table 5.1. Institutional Review Board 
permission and informed patient consent were obtained.  
 
5.2.2. PET/CT image acquisition  
We used a combined PET/64-detector CT instrument (GE Healthcare Technology, 
Waukesha, WI) to obtain images. Patients fasted for 6h prior to scans. PET/CT images 
were acquired 3h after injecting 200MBq of 18F-FDG, according to recognized 
protocol219, 223, 344, 348. CT was performed using 64 × 3.75mm detectors, a pitch of 1.5 
and 5mm collimation (140kVp and 80mA in 0.8s) over the patient’s abdominal aorta. 
The pixel size for the unenhanced CT images used in this study was 0.98mm x 0.98mm. 
Maintaining the patient position, an 18F-FDG PET emission scan was performed and 
covered an area identical to that covered by CT.  All acquisitions were in 2D mode 
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(8min/bed position). Transaxial emission images of 3.27mm thickness (pixel size 
3.9mm) were reconstructed using ordered subsets expectation maximization332 with 2 
iterations and 28 subsets.  The z-axial field of view was 148.75mm, resulting in 47 
slices per bed position.  
 
5.2.3. CT texture analysis 
Image heterogeneity of the AAA via CTTA using a filtration-histogram technique was 
assessed using TexRAD (TexRAD Ltd, Somerset, UK), a proprietary software 
algorithm developed by Ganeshan et al375. CTTA of AAA was derived by filtering each 
CT image to obtain: fine texture scale, ie filter value 1.0, approximately 2mm in width 
(radius) ; medium texture scale, ie filter value 1.5-2.0, approximately 3-5mm in width 
(radius); and coarse texture scale, ie filter value 2.5, approximately 6mm in width 
(radius). The filtered images were quantified using histogram-based parameters. These 
texture parameters include standard-deviation (SD) that relates the degree of variation 
from the mean pixel value (SD, width of the histogram) and kurtosis (K) that reflects 
pointedness of the histogram. SD increases approximately in proportion to the square-
root of the number of features highlighted and their mean intensity difference compared 
to background (ie dark and bright features are both positive). Kurtosis is related 
inversely to the number of features highlighted (whether bright or dark) and increases 
by intensity variations in highlighted features. By quantifying these different image 
features (size, concentration and density-variation of the features highlighted by the 
filter) within a tissue (representing the different aspects of tissue heterogeneity), 
computed image texture analysis algorithms have the potential to provide additional 
morphological information relating to tissue heterogeneity376. A detailed description of 
the above image filtration and quantification is described in the appendix. CTTA was 
performed by an experienced reader (CW) under supervision from a researcher (BG) 
with 7 years’ experience in texture analysis of radiographic images, who aided in inter-
observer variability measurements. Both were blinded to the results of FDG-PET 
analysis and aneurysm growth rates. Interclass correlation coefficient (ICC) to assess 
inter-observer variability was performed by CW and BG. For each patient, a whole 
vessel analysis of the imaged AAA was performed. CTTA was measured over the 
whole volume of each AAA considering all the individual axial slices. A region of 
interest (ROI) was placed to include the aneurysm wall and content (Figure 5.1). To 
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adjust for textural features of background blood pool or luminal contents heterogeneity 
measurements were adjusted by dividing AAA heterogeneity measurements by the 
corresponding blood pool heterogeneity measurements for each aneurysm. The 
methodology to measure the CTTA for the blood pool was similar to the way CT signal 
heterogeneity for AAA was measured.  The CTTA for blood pool was measured by 
placing a ROI to include AAA luminal contents (including intra-luminal thrombus and 
excluding AAA wall) on each of the axial CT slices comprising the whole volume 
(Figure 5.2)348, thereby, aiming to exclude heterogeneity changes derived from intra-
luminal thrombus. The CT slices for analysis were comparable in terms of anatomical 
location to the PET image employed for measuring 18F-FDG uptake. The ROI enclosing 
the AAA on CT was drawn using the same guidelines as for PET image analysis. 
However, for PET measurements of blood pool activity, average 18F-FDG uptake of 
inferior vena cava (at least 8 measurements) was used. The CT ROI were further refined 
by excluding areas of air with a thresholding procedure which removed from analysis 
any pixels with attenuation values below −50 HU.  
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Figure 5.1 Computer tomography texture analysis of AAA 
wall and content - (a) Conventional infra renal AAA CT 
image. (b–d) Corresponding images selectively displaying 
filtration of the histogram at (b) fine (2mm in width), (c) 
medium (3-5mm in width), and (d) coarse (6mm in width) 
texture.   
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Figure 5.2 Computer tomography texture analysis of AAA 
luminal content including the blood pool and intraluminal 
thrombus (AAA wall excluded). (a) Conventional infra 
renal AAA CT image. (b–d) Corresponding images 
selectively displaying filtration of the histogram at (b) fine 
(2mm in width), (c) medium (3-5mm in width), and (d) 
coarse (6mm in width) texture.   
 
5.2.4. PET/CT image analysis 
 
PET/CT images were reviewed both by a dual accredited radiologist/nuclear medicine 
physician with a special interest in cardiovascular imaging and with greater than four 
years’ experience of measuring vascular 18F-FDG uptake who was blinded to clinical 
data, and by a surgeon with a special interest in vascular imaging, supervised by a dual 
accredited radiologist/nuclear medicine physician. PET/CT images were loaded onto a 
Xeleris workstation (GE Healthcare Technology, Waukesha, WI). Similar to CTTA, we 
also performed a whole vessel analysis of the imaged AAA316. 
Through visual assessment of axial and coronal planes of the imaged aorta, 
measurements were commenced on axial images from distal to the neck of the AAA and 
proximal to distal descending aorta where vessel diameter normalizes to include the 
whole volume AAA. AAAs extending into the bifurcation were measured up to the 
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level of the bifurcation of the aorta.  A region of interest (ROI) was placed to include 
the aneurysm wall and content. The maximum standardized uptake value (SUVmax) of 
the AAA was calculated subsequently for each axial level and the values were then 
summed and divided by the total number of axial images to obtain an average SUVma x 
for the whole AAA. In order to adjust for back ground metabolic activity and potential 
false high uptake values a target-to-back ground ratio (TBRmax) was calculated by 
dividing the average AAA SUVmax by an average blood ROI (at least 8 venous ROI 
measurements), estimated from the inferior vena cava223.  In addition, for each 
individual aortic aneurysm we identified the site of maximum aortic wall 18F- FDG 
uptake. At this site we measured the SUV, yielding in each patient, a single site SUVma x 
and TBR value, as previously described 222, 348. The SUV is the decay-corrected tissue 
concentration of 18F-FDG (in kBq/g), adjusted for injected 18F-FDG dose and body 
weight (in kBq/g).  
 
5.2.5. Duplex ultrasound image acquisition 
Study patients underwent abdominal ultrasound at the time of PET/CT examination and 
subsequently routine ultrasound scan measurements at 6 and 12 months post PET/CT. 
In keeping with Thapar et al347, maximal anteroposterior (AP) external aortic wall 
diameter was recorded on each occasion. To adjust for baseline aneurysm size we 
calculated expansion at 12 months divided by aneurysm size at time of PET/CT scan 
(adjusted for baseline size longitudinal AAA expansion). Specialist vascular scientists 
(with greater than three years’ experience), who were blinded to CTTA, FDG uptake 
results and expansion results, performed the surveillance ultrasound scans (Philips, HDI 
5000, C5-2, Curved Linear Probe).  
 
5.2.6. Statistical analysis  
Statistical analyses were performed using SPSS for Windows version 18.0. After data 
were examined for normality, non-parametric statistical tests were performed, and 
median values and interquartile range (IQR) presented. Spearman’s rank correlation was 
used to assess the association between AAA CTTA, aortic wall 18F-FDG uptake values 
and corrected for baseline longitudinal AAA growth. Univariate analysis of clinical 
factors was performed and where appropriate adjustments were made to account for 
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confounding clinical factors. Intra-class correlation coefficient was used to assess inter-
observer test/re-test results. Sensitivity, specificity and the area under the receiver-
operating-characteristics (ROC) curve were established for significant parameters that 
identified annual AAA expansion >2mm. The point on the ROC curve furthest from the 
line of no discrimination was considered the optimum (diagnostic) threshold for 
predicting a significant AAA expansion.  Statistical significance was set at 5%. 
 
5.3. RESULTS 
Ten patients were lost to follow-up at 12 months (non-aneurysmal deaths n=2, withdrew 
from study n=2, failed to attend ultrasound scan n=5, emergency AAA repair n=1), 
leaving 40 patients (36 men, 4 women, median age 74y (range 60-85y) for analysis 
(Table 5.1). The patient who underwent an emergency AAA had a symptomatic rapid 
expanding AAA (expansion of >10mm per annum). 
 
Table 5.1 Summary of the medical details of the patient population 
History or Symptoms  N = 40 
Age (median, range) 74 (60-85) y 
Male 36 
Female 4 
Ischaemic heart disease 13 
Raised lipids 30 
Statin use 28 
Diabetes 4 
Hypertension 31 
Current or previous smoker 22 
Median maximal AAA diameter  49.5 (IQR 43.0-53.0)mm * 
51.0 (IQR 41.0-55.8)mm † 
 
* Baseline median maximal AAA diameter as measured on duplex ultrasound 
† Baseline median maximal AAA diameter as measured on CT 
 
 
The baseline median maximal aortic AP diameter on ultrasound was 49.5 (IQR 43.0-
53.0)mm versus 51.0 (IQR 41.0-55.8)mm on CT (r=0.945; p< 0.0001) (paired t-test; 
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t(39)= -2.29, p=0.027). The median maximal aortic AP diameter 12 months following 
the PET/CT imaging was 53.0 (IQR 44.3-57.5)mm. The median aneurysm expansion at 
12 months was 2.0 (IQR 0.0-4.0)mm (range 0-9mm). The median annual growth 
adjusted for baseline size was 4.4% (IQR 0.0-9.2). The median corrected whole 
aneurysm texture parameters are summarized in Table 5.2. The median maximal whole  
abdominal aortic wall 18FDG uptake (SUVmax) was 1.798 (IQR 1.463-2.256). The 
median whole AAA TBRmax was 1.200 (IQR 1.100-1.506). The median single site 
SUVmax was 1.796 (IQR 1.500-2.402). 
 
Table 5.2 The median whole AAA texture parameters at fine, medium and coarse filter levels for 
standard deviation (SD) and kurtosis (K) 
Filter Standard deviation* Range  
(min-max) 
Kurtosis † 
 
Range  
(min-max) 
Fine 2.66 1.20-7.54 28.06 -1113.12-502.07 
Medium 4.94 1.45-10.51 7.22 -322.09-370.07  
Coarse 3.57 1.59-11.56 4.71 -56.89-220.70 
 
†Texture parameter kurtosis (K), which is quantified from filtered images, does not have units. This 
parameter describes the shape of the histogram: positive kurtosis suggests the histogram is pointed, 
negative kurtosis suggests the histogram is flatter, 0 kurtosis suggest the histogram is Gaussian. 
*SD takes on the unit of the original data. In this instance it is the filtered image which is an intensity 
image with positive and negative values representing features of a particular size based on the filter. 
Unlike the conventional image units that are reported in Hounsfield units (HU), the filtered image does 
not have any units and therefore SD too is without units.  
 
 
5.3.1. Texture-metabolic association for AAA 
Whole AAA coarse texture SD showed an inverse association with AAA SUVmax (rs=- 
0.456, p=0.003) (Figure 5.3). Furthermore, we observed a trend between fine texture K 
and AAA TBRmax (rs=0.324, p=0.041). Correlations between texture parameters and 
AAA metabolic activity, before and after adjusting for confounding clinical factors 
(back pain), are summarized in Table 5.3.   
 
 
 111 
 
 Chapter 5 AAA textural analysis, metabolic activity and aneurysm expansion 
 
Figure 5.3 Scatter plot of whole AAA metabolic 
activity measured as SUVmax and coarse texture 
parameter standard deviation (SD) (n=40). 
 Spearman correlation coefficient rs (with p-value) 
between the two variables is presented at top right.  
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Table 5.3 The correlation of texture parameters kurtosis (K) and standard deviation (SD) with 
metabolic activity measured as FDG uptake before and after adjusting for confounding 
clinical factors (back pain) 
Texture 
parameter 
filter 
 SUVmax 
(Spearman rs= ; p=) 
TBRmax 
(Spearman rs= ; p=) 
Fine  
K       
 
SD 
 
 0.165; 0.310 
 0.173; 0.291† 
-0.419; 0.007* 
-0.449; 0.004*† 
 
 0.324; 0.041* 
 0.330; 0.043*† 
-0.186; 0.251 
-0.200; 0.222† 
Medium 
K 
 
SD 
 
  0.187; 0.248 
  0.204; 0.213† 
 -0.435; 0.005* 
 -0.463; 0.003*†  
 
 0.212; 0.188 
 0.224; 0.170† 
-0.136; 0.402 
-0.148; 0.370† 
Coarse 
K 
 
SD 
 
 
 0.045; 0.782 
 0.066; 0.691† 
-0.456; 0.003* 
-0.473; 0.002*† 
 
 0.073; 0.656 
 0.086; 0.602† 
-0.095; 0.560 
-0.101; 0.541† 
 
*Indicates significance set at < 0.05 
† Correlation after adjusting for clinical factors (back pain)  
  
5.3.2. Aortic CTTA and future AAA expansion 
There was no significant difference in AAA expansion for any of the clinical variables 
(Table 5.4). In 2/40 (5%) patients who suffered from back pain, the AAA growth rate at 
one year was borderline significantly larger than those who did not suffer back pain 
(minimum adjusted growth: 0 vs 9.3%; maximum adjusted growth: 16.7% vs 15.5%; 
p=0.069). 
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Table 5.4 Univariate analysis of clinical factors to identify confounding factors for AAA expansion 
adjusted for baseline AAA size and annual expansion > 2mm 
 Clinical factors 
 
AAA expansion adjusted for baseline 
AAA size 
Median (IQR) 
 (p=) Annual expansion     > 2mm 
N (%) 
No expansion            Expansion 
OR  (p=) 
 
       
 Sex (F | M) 4:36 
 Hypertension (N|Y) 8:32 
 Beta-blocker use (N|Y) 24:16 
 ACE-inhibitor use (N|Y) 25:13 
 Ischaemic heart disease 27:13 
 Raised lipids (N|Y) 11:29 
 Statin use (N|Y) 9:31 
 Smoking (N|Y) 35:5 
 Diabetes (N|Y) 35:4 
0.47 (0.06; 1.04) 
0.64 (0.10 ; 0.94) 
0.55 (0.19; 0.94) 
0.42 (0.00; 0.94) 
0.53 (0.00; 0.93) 
0.71 (0.38; 0.93) 
0.73 (0.19; 1.23) 
0.45 (0.19; 0.87) 
0.45 (0.19; 0.93) 
0.44 (0.00; 0.92) 
0.41 (0.00; 0.86) 
0.38 (0.00; 0.85) 
0.45 (0.10; 0.72) 
0.42 (0.00; 0.91) 
0.39 (0.00; 0.91) 
0.42 (0.00; 0.87) 
0.00 (0.00; 0.94) 
0.00 (0.00; 1.00) 
0.964  
0.550 
0.167 
0.963 
0.630 
0.257 
0.359 
0.385 
0.223 
13/15 (86.7% ♂)  
13/15 (86.7) 
7/15 (46.7) 
5/14 (35.7) 
5/15 (33.3) 
13/15 (86.7) 
13/15 (86.7) 
3/15 (20) 
3/14 (21.4) 
23/25 (92% ♂) 
19/25 (76) 
9/25 (36) 
8/24 (33.3) 
8/25 (32) 
16/25 (64) 
18/25 (72) 
2/25 (8) 
1/25 (4) 
1.8 (0.622) 
0.5 (0.686) 
0.6 (0.527) 
0.9 (1.000) 
0.9 (1.000) 
0.3 (0.158) 
0.4 (0.440) 
0.3 (0.345) 
0.2 (0.123) 
 Back    Back pain (N|Y) 38:2 0.42 (0.00; 0.83) 0.93 - 1.24 0.069 0/15 (0) 2/25 (8) 0.6 (0.519) 
 
*Indicates significance set at < 0.05 
 
 
Medium texture K positively correlated with absolute future AAA expansion (rs=0.470, 
p=0.002, Figure 5.4). Medium texture K also positively correlated with future AAA 
expansion adjusted for baseline AP AAA diameter (rs=0.343, p=0.030). Coarse texture 
SD positively correlated with future AAA expansion adjusted for baseline AP AAA 
diameter (rs=0.325, p=0.041). Correlations between AAA texture parameters and future 
expansion, before and after adjusting for confounding clinical factors (back pain), are 
summarized in Table 5.5.    
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Figure 5.4 Scatter plot of AAA expansion at 1y and 
medium coarseness texture parameter kurtosis (K) 
(n=40).  Spearman correlation coefficient rs (with p-
value) between the two variables is presented at top 
right  
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Table 5.5 The correlation of texture parameters kurtosis (K) and standard deviation 
(SD) with future growth before and after adjusting for confounding clinical factors  
Texture 
parameter 
filter 
 Absolute AAA expansion 
at 1 year 
 
(Spearman rs= ; p=) 
AAA expansion 
adjusted for baseline 
AAA Size 
(Spearman rs=; p=) 
Fine  
K         
 
 SD 
 
 
0.422; 0.007* 
0.454; 0.004*† 
-0.208; 0.198  
-0.129; 0.433† 
 
0.119, 0.465 
0.083; 0.617† 
0.212; 0.189 
0.315; 0.051† 
Medium  
K 
 
SD 
 
 
0.470; 0.002* 
0.456; 0.004*† 
-0.184; 0.256 
-0.970; 0.557† 
 
0.343; 0.030* 
0.274; 0.091† 
0.325; 0.041* 
0.421; 0.008*† 
Coarse  
K 
 
SD 
 
 0.401; 0.010* 
 0.436; 0.025*† 
-0.139; 0.392  
-0.051; 0.760† 
 
0.226; 0.161 
0.142; 0.389† 
0.312; 0.050* 
0.386; 0.015*† 
 
*Indicates significance set at < 0.05 
† Adjusted for clinical factors 
 
5.3.3. Texture analysis comparison between aneurysmal and normal aorta  
Whole vessel CTTA of aneurysmal compared to normal aorta was significantly 
different for coarse SD (Wilcoxon signed rank test, p=0.001, Figure 5.5). 
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Figure 5.5 Box plot showing a significant difference 
between coarse texture parameter SD of aneurysmal 
compared to normal aorta (Wilcoxon signed rank 
test, p=0.001) 
 
5.3.4. Inter-observer variability for whole aneurysm CTTA 
Intra-class correlation coefficient (ICC) between observers were as follows: fine (K, 
r=0.987, 95% CI 0.948-0.997, p<0.0001 and SD,  r=0.993, 95% CI 0.975-0.998, 
p<0.0001), medium (K, r=0.954, 95% CI 0.797-0.989, p<0.0001 and SD, r=0.978, 95% 
CI 0.916- 0.994, p=0.001) and coarse texture (K, r=0.963, 95% CI 0.841- 0.990, 
p<0.001 and SD, r=0.995, 95% CI 0.980- 0.999, p<0.001).        
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5.3.5. Aortic 18F-FDG uptake and future AAA expansion 
In addition, we observed that SUVmax correlated inversely with future expansion at one 
year (rs=-0.383, p=0.015, Figure 5.6). A borderline significant inverse trend was 
observed between highest single site TBRmax and annual expansion (rs=-0.304, 
p=0.057). No significant association between average AAA TBRmax and annual 
expansion was found (rs=- 0.021, p=0.889).  
 
 
Figure 5.6 Scatter plot of AAA expansion at 1y 
adjusted for baseline aneurysm size and whole 
AAA metabolic activity measured as SUVmax 
(n=40).  Spearman correlation coefficient rs (with 
p-value) between the two variables is presented at 
top right.  
 
5.3.6. Diagnostic criteria for imaging parameters to identify significant AAA 
expansion  
We observed no statistically significant association between clinical variables and 
annual AAA expansion ≥ 2mm (Table 5.4). AAA medium texture K identified patients 
with significant annual AAA expansion (> 2mm). In particular, a kurtosis value > 15 
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identified patients with AAA expansion (> 2mm) with a sensitivity of 80% and a 
specificity of 73% (AUC= 0.813, p= 0.001, 95% CI 0.672-0.955). In a multiple logistic 
regression, the relationship between medium texture K and AAA expansion persisted 
after adjusting for clinical variables of ischaemic heart disease, hypertension, beta 
blocker use, ACE-inhibitor use, raised lipids, statin use, diabetes and back pain 
(OR=1.348, 95% CI 1.072 - 1.695 , p=0.011, c=0.917). Medium texture K (adjusted for 
back ground blood pool activity) also identified patients with significant AAA 
expansion (>2mm). A kurtosis value > 3 identified patients with AAA expansion 
(>2mm) with a sensitivity of 68% and a specificity of 60% (AUC=0.725, p=0.018, 95% 
CI 0.569; 0.881). The relationship between medium texture K (adjusted for back ground 
blood pool activity) and AAA expansion remained statistically significant after 
adjusting for clinical variables in a logistic regression model (OR=1.036, 95% CI 1.002 
- 1.072, p=0.038). Coarse texture SD did not identify patients with significant annual 
AAA expansion (AUC=0.373, 95% CI 0.171 - 0.575, p=0.103). There was no 
relationship between SD (adjusted for back ground blood pool texture) and AAA 
expansion (AUC=0.629, 95% CI 0.422 - 0.836, p=0.106). There was no correlation 
between texture K and SD values (Spearman rs=-.214, 95% CI (-0.164; 0.154)) or 
texture K and SD adjusted for back ground blood pool texture (Spearman rs=-0.077, 
95% CI (-0.391; 0.254)). 
 
5.4. DISCUSSION 
 
This project represents the first use of CT signal heterogeneity to investigate the 
relationship between AAA heterogeneity and future AAA growth. The results suggest 
CTTA assessment in small aortic aneurysms may be considered as a risk-stratification 
tool for validation in future prospective studies to identify aneurysms at risk of 
significant expansion. In addition CT textural data may reflect AAA metabolism as 
measured by 18F-FDG PET.   
 
Studies have explored risk-stratification properties of texture analysis in symptomatic 
atherosclerotic carotid plaque that correlated with ipsilateral stroke377 and ability to 
predict incidence of silent infarcts in patients who underwent carotid endarterectomy378. 
Furthermore, CT-measured arterial wall thickness and volume in conjunction with 
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functional PET signal has been utilized in assessment of atherosclerosis extent379; 
however, our work is the first application of CTTA as measure of aneurysmal 
atherosclerotic plaque texture in relation to future expansion. Our findings suggest 
aortic aneurysms with greater medium CT signal heterogeneity K may be more likely to 
exhibit greater expansion. In addition, increased coarse AAA heterogeneity SD and 
decreased AAA medium heterogeneity K may be present in aneurysms that exhibit 
lower metabolic activity. On a histogram, increased K and SD values may suggest 
surface anatomical textural changes in AAA, possibly reflecting underlying 
pathobiology and associated metabolic activity. These findings have to be rationalized 
in light of current histological validated evidence. This CTTA technique has identified 
possible biological correlates for CTTA parameters (SD at medium to coarse feature-
scale) and histological markers of hypoxia (pimonidazole) and angiogenesis (CD34, 
VEGF) in non-small cell lung and colorectal cancers368, 380. Furthermore, recent test/re-
test data from clinical studies in rectal cancer and test-objects demonstrate 
reproducibility of CTTA results381. Regions of hypoxia and angiogenesis have been 
implicated in both atherosclerosis382, 383 and development of AAA134, 190, 384. In AAA, 
Vorp et al identified localized areas of hypoxia with possible localized mural 
neovascularization and inflammation in regions of thicker intraluminal thrombus190. We 
and other researchers argue that increased CT signal heterogeneity K of vasculature may 
reflect tissue vascular density or increased angiogenesis372-374. It is hypothesized that 
normal vessel walls can be considered to have well organized long microvascular 
channels, which become disorganized with angiogenesis, resulting in a mix of long 
channels and short vascular hot spots, causing flow voids and hypoxia. The histogram 
quantification can reflect image signal heterogeneity which may constitute the size, 
concentration and density (in relation to the background) of textural features within the 
vessel wall enhanced by the filter and  may be associated with adverse biology376. 
 
In a large observational study, Thompson et al reported that an adjusted annual growth 
rate of  >2mm was significantly associated with clinical events such as intervention or 
rupture21. Since medium AAA heterogeneity parameter K was significantly different in 
aneurysms, growing at least 2mm in one year, it may be rationalized that AAAs 
expanding 2mm or more per annum might demonstrate increased aneurysm wall 
vascular density. This is in keeping with histological studies showing increased AAA 
wall angiogenesis and associated AAA adverse events169, 384. Analogous findings have 
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already been shown in oncology, where coarse texture parameters on CT correlated with 
hepatic blood flow, glucose metabolism313, 373, 374, disease extent374 and patient 
survival368, 369, 373, 385, 386, establishing its role as a potential biomarker in cancer. 
However, CTTA may measure the complexity of the shape of the edge of the AAA 
thrombus wall rather than angiogenesis of AAA wall. Therefore, in our study we 
performed CTTA of AAA luminal contents, including intra-luminal thrombus and 
excluding AAA wall, to exclude heterogeneity signals derived from intra-luminal 
thrombus. Nevertheless, histological PET/CT heterogeneity studies are needed to 
underpin structural characteristics associated with significant disease progression to 
provide possible explanations for these study findings.  
 
The additional finding of inverse correlation between 18F-FDG uptake and future 
expansion may be explained by current biological evidence suggesting that 18F-FDG 
uptake in humans is related to the degree of inflammatory markers and infiltrate in 
aortic aneurysms 316 and other arteries219. We and other researchers168, 169, 354 suggest 
that an initial inflammatory phase followed by a dilatation phase with calcification 
possibly represents a late burn-out stage of atherosclerosis316. Furthermore, the potential 
effects of statins in reducing or preventing AAA expansion387 needs consideration. In 
our study cohort 28 of 40 patients were receiving statins. This may explain the annual 
aneurysm expansion of 2.0mm, (IQR 0.0-4.0). 
 
In tumour studies, both FDG PET and CTTA have been described in measuring 
response to therapy355, 388. Our study identified that CT texture characteristics (and FDG 
PET uptake) derived from baseline PET/CT images are associated with prospective 
AAA growth rate, thus validating the role of these modalities in studying AAA and 
providing a foundation for further larger studies.  
 
There are study limitations and technical considerations when interpreting our findings.  
In this preliminary analysis patients underwent non-enhanced PET/CT for aneurysm 
assessment. Nevertheless, CTTA without IV contrast has been shown to provide useful 
information on underlying tumour heterogeneity375, 386 and has the added benefit that 
potential effects of contrast administration are nullified. A 2mm AAA wall axial 
thickness389 was measured where accurate delineation of AAA wall could not be 
attained. In addition, in this study we performed a whole vessel type texture analysis to 
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avoid misleading findings on limited aneurysm area, thereby increasing validity and in 
keeping with recommended AAA PET/CT analysis. The study population size of 50 is 
commensurate with a proof of concept investigation and compares favourably with 
many initial functional arterial PET studies357, 358. Nonetheless, larger and more 
extended studies are needed. Furthermore, we recognize the limitations associated with 
small participant numbers, the exclusion of age and baseline AAA diameter in the 
logistic regression analysis; and that information on time from AAA diagnosis to 
recruitment in this study is lacking. This may allow for the possibility of by-chance 
findings, potential selection bias and or lack of generalizability. Models used in finite 
element analysis and AAA wall stress studies may define different regions of interest as 
described in our study. It would, however, be interesting to assess if areas of high wall 
stress are more heterogeneous. More histological validated evidence linked with CTTA 
is needed. However, histology as ‘gold standard’ for tissue characterization may be 
limited since  preparation removes calcium and lipid which may affect structural 
integrity of tissue390. In common with other  expansion studies, there are 
methodological challenges, ie the change in aortic diameter over time is small and the 
measurement of aortic diameter using ultrasound (and to a lesser extent CT) has an error 
margin of 2 to 3mm, which is larger than the annual expansion of many small AAAs364.  
 
In conclusion, in this chapter we present the first application of CT textural analysis to 
investigate the relationship between AAA heterogeneity and future AAA growth. Our 
results suggest that AAA CT heterogeneity may be considered as a risk stratification 
tool in future prospective studies to identify aneurysms at risk of significant expansion. 
In addition we observed a potentially interesting metabolic correlate between CT 
textural features and AAA metabolism on PET that could be further investigated to 
provide insight into AAA biology. 
 
Summary of findings: 
 
 Coarse texture SD showed an inverse association with SUVmax.  
 Fine texture K correlated with TBRmax.  
 Medium coarse texture K correlated with future AAA expansion.  
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 CTTA parameters were significantly different for coarse SD when aneurysmal and 
normal aorta were compared.  
 SUVmax correlated inversely with future expansion.  
 
The next chapter assess the relationship between serum biomarkers of vascular 
inflammation and 18F-FDG uptake in small AAA to establish the role of PET/CT in 
quantitative assessment of metabolic activity in AAAs and the clinical significance 
thereof.  
  Chapter 6 Serum biomarkers of inflammation and AAA metabolic activity 
CHAPTER 6. RELATIONSHIP BETWEEN SERUM BIOMARKERS AND 18F-FDG 
AORTIC ANEURYSM UPTAKE ON PET/CT 
 
6.1. INTRODUCTION 
 
Inflammation involving infiltration of macrophages, lymphocytes, neutrophils and mast 
cells has been shown to be critical for the formation and progression of AAA; however, 
the molecular mechanisms of AAA pathogenesis are not fully understood304. 
Inflammatory serum biomarkers have been reported to be associated with the presence 
of AAA111, 391, 392 and rupture327, 393; the relationship between serum biomarkers and 
AAA progression is currently unclear, with studies reporting negative results394. 
 
Up until now, PET/CT biomarker studies have focussed on different aspects of the 
atherothrombotic process. Wu et al reported a link between circulating matrix 
metalloproteinases (MMP-1) and 18F-FDG PET in symptomatic carotid disease 
subjects216. Other vascular PET researchers observed associations between MMP-3 
levels and inflammation in the aorta316. Since inflammation is central in AAA 
pathobiology and progression, it is hypothesized that circulating inflammatory serum 
biomarker levels are associated with the AAA metabolic activity in the patient with 
small AAA. The relationship between AA wall metabolic activity as measured by 18F-
FDG PET/CT and recognised circulating vascular serum biomarkers remains to be 
established.   
 
For these reasons, we assessed correlations between serum biomarker levels of high 
sensitivity MMP-9 (hsMMP-9), high sensitivity MMP-2 (hsMMP-2), high sensitivity 
interferon-gamma (hsIFN-γ) and high sensitivity C-reactive protein (hsCRP) with the 
tracer signal derived from PET in patients with small AAA under routine surveillance.  
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6.2. MATERIALS AND METHODS 
 
6.2.1. Patients and baseline characteristics  
During a 12-month period, patients presenting to one of our institutions with AAA and 
deemed suitable for surveillance were invited to participate in this serological and 
PET/CT study.  Twenty-four consecutive patients (20 men, 4 women, median age 74y 
(SD+-6.23) with small AA under routine surveillance were recruited. All patients had 
an infrarenal AAA. Patients with thoracic, inflammatory and or symptomatic AAA were 
excluded. Sixteen healthy control subjects were recruited from a social club for 
biomarker analysis. The baseline demographics for subjects and controls are presented 
in Table 6.1. Seven patients had at least 3 risk factors for atherosclerosis. An example of 
AAA wall 18F-FDG uptake is shown in Figure 6.1.  
 
Table  6.1 Summary of the medical details of the patient population and control group 
History or symptoms Participants (n) Control group (n) 
Age (mean, SD) 74 y (+-6.23) 65 y (+-3.68) 
Male 20 11 
Female 4 5 
Back pain  1 - 
Ischaemic heart disease 9 - 
Raised lipids 10 3 
Diabetes 2 - 
Hypertension 19 - 
Current or previous smoker 9 11 
Statin use 20 - 
ACE-inhibitor use 6 - 
Beta-blocker use 12 - 
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Figure 6.1 Sagittal fused PET/CT image of an AAA showing 
18F-FDG uptake in the aneurysm 
 
6.2.2. PET/CT image acquisition 
A combined PET/64-detector CT instrument (GE Healthcare Technology, Waukesha, 
WI) was used to obtain images. Patients fasted for 6h prior to scans. PET/CT images 
were acquired 3h after injecting 200MBq of 18F-FDG, according to recognized 
protocol219, 223, 344, 348. CT was performed using 64 × 3.75mm detectors, a pitch of 1.5 
and 5mm collimation (140kVp and 80mA in 0.8s) over the patient’s abdominal aorta.  
Maintaining the patient position, an 18F-FDG PET emission scan was performed and 
covered an area identical to that covered by CT.  All acquisitions were in 2D mode 
(8min/bed position). Transaxial emission images of 3.27mm thickness (pixel size 
3.9mm) were reconstructed using ordered subsets expectation maximization332 with 2 
iterations and 28 subsets.  The axial field of view was 148.75mm, resulting in 47 slices 
per bed position.  
 
6.2.3. PET/CT image analysis 
PET/CT images were reviewed by an experienced reader (CW) with a special interest in 
vascular imaging, supervised by a dual accredited radiologist/nuclear medicine 
physician (LJ). PET/CT images were loaded onto a Xeleris workstation (GE Healthcare 
Technology, Waukesha, WI). We performed a whole vessel analysis of the imaged 
AAA223.  A region of interest (ROI) was placed to include the aneurysm wall and 
content. The maximum tracer uptake (SUVmax) of the AAA was calculated subsequently 
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for each axial level and the values were then summed and divided by the total number 
of axial images to an average (SUVmax) for the whole AAA. Whole AAA target-to-
background ratio (TBRmax) was calculated by dividing the average absolute SUVmax by 
an average blood ROI (at least 8 venous ROI measurements), estimated from the 
inferior vena cava319.  The SUV is the decay-corrected tissue concentration of 18F-FDG 
(in kBq/g), adjusted for injected 18F-FDG dose and body weight (in kBq/g).  
 
6.2.4. Biomarker measurements 
Biomarker analyses were carried out at the Adipokines and Metabolism Laboratory at 
UCL (London, UK). Biomarkers were chosen to cover different aspects of the AAA 
pathobiological inflammatory process. The levels of hsMMP-9, hsMMP-2, hsIFN-γ and 
hsCRP were analysed and compared to healthy control subjects.  Peripheral venous 
blood samples were collected prior to the PET/CT, before tracer injection. In control 
subjects, venous blood samples were taken following consent. The samples were 
collected with potassium ethylenediaminetetraacetic acid tubes and were centrifuged to 
obtain serum aliquots (3500rpm for 15mins). Aliquots were stored at −80°C until 
assayed. High sensitivity IFN-γ and hs-CRP were measured by (enzyme-linked 
immunosorbent assay) ELISA (GenWay Biotech and Gen-Probe Diaclone SAS Inc.). 
The lowest detectable level of the hs-CRP assay was 0.005 mg/dL.  High sensitivity 
MMP-9 and MMP-2 were determined by a commercially available ELISA, using the 
QuickZyme Biosciences Assay System (Netherlands). Circulating serum biomarker 
assays were performed twice and average biomarker levels are presented. 
Manufacturers’ protocols were meticulously followed. Serum samples were diluted in 
the appropriate calibrator diluent and added to wells with standards and appropriate 
controls, then left to incubate. Washed wells were further incubated with the diluted 
biotinylated detection antibody specific to the analytes of interest added. Stop solution 
was added to each well, following a further wash to expose unbound biotinylated 
antibody. The suspended biomarker levels were read using the Luminex analyzer 
(BioRad, Austin, Texas). 
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6.2.5. Statistical analysis  
Each data set was analysed appropriately following tests for normality. Continuous 
variables are displayed by their mean and SD. For comparison of circulating serum 
biomarker levels between subjects and controls, and to explore the associations between 
tracer variables and biomarkers, linear regression analyses were performed. Average 
whole AAA tracer uptake values were used to compare aortic wall tracer uptake values 
with clinical factors and circulating biomarkers. Student’s t-test was used to compare 
FDG tracer uptake and clinical factors.  Mann-Whitney U test was used to compare 
biomarker measurements across clinical factor groups. To investigate associations we 
performed Pearson’s correlation and Spearman’s rank correlation coefficients as 
appropriate.  Statistical tests were performed with SPSS (Version 18.0, SPSS Inc, 
Chicago, Ill). Statistical significance was set at 5%. Corrections were applied for 
differences in age, gender, statin use and smoking habits between subjects and controls. 
 
6.3. RESULTS 
 
The mean whole AAA SUVmax was 2.188 (SD+0.541). The mean whole AAA TBRmax 
was 1.414 (SD+0.312). The mean AAA size at the time of PET/CT was 4.31cm 
(SD+1.03).  
 
Table 6.2 Summary of the mean levels of studied circulating biomarkers 
Circulating biomarker Mean SD 
hsMMP-9 5.692 +5.83 
hsMMP-2 2.256 +1.35 
hsIFN-γ 1.850 +3.80 
hsCRP 3.194 +2.77 
 
 
6.3.1. Clinical factors and associations with serum biomarkers  
We observed a lower AAA SUVmax uptake in subjects with hypertension (p=0.040, CI 
=- 0.900 – - 0.022) (Figure 6.2). Subjects with raised lipids (p=0.022), hypertension 
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(p=0.005) and ischemic heart disease (p=0.004) had significantly higher levels of 
hsMMP-9 (Figure 6.3). Subjects with raised lipids (p=0.015), ischaemic heart disease 
(p=0.027) and ex-smokers (p=0.033) had significantly higher levels of hsMMP-2. In 
subjects who gave up smoking, we observed higher levels of hsCRP (p=0.047). No 
other significant differences were found across clinical risk factors for FDG uptake and 
circulating biomarkers. 
 
Figure 6.2 Aortic wall metabolic activity variations 
among different risk factor groups  
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Figure 6.3 High sensitivity metalloproteinase-9 
variations among different risk factor groups  
Abbreviations: HTN, hypertension; IHD, ischaemic heart disease; * p< 0.05 
 
6.3.2. Increased levels of hsMMP-9 & hsMMP-2 were observed in AAA subjects 
compared to controls.  
hsMMP-9 and hsMMP-2 levels adjusted for age, gender, hypertension, ischaemic heart 
disease, raised lipids and statin use were significantly higher in subjects versus controls 
(p<0.001). There was borderline significantly increased levels of hsCRP observed in 
subjects versus controls (p=0.057). There was no significant difference found between 
subjects and controls for hsIFN-γ (p=0.501). 
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Figure 6.4 Box plot showing higher levels of 
circulating high sensitivity metalloproteinase-9 in 
subjects compared to controls (p<0.001) 
 
6.3.3. AAA wall FDG uptake does not correlate with levels of circulating 
inflammatory biomarkers 
No correlations were found for whole AAA SUVmax and levels of hsMMP-9 (rs=-0.037, 
p=0.865), hsMMP-2 (rs=-0.226, p=0.239), hsINF-γ (r =0.210, p=0.404) and hsCRP (rs=-
0.009, p=0.966).  Furthermore, there were no correlations for whole AAA TBRmax and 
levels of hsMMP-9 (rs=0.120, p=0.576), hsMMP-2 (rs =-0.059, p=0.806), hsIFN-γ 
(rs=0.029, p=0.908) and hsCRP (rs=0.138, p=0.521).  
 
6.4. DISCUSSION 
 
This observational project investigates for the first time the relationship between 
circulating serum biomarkers and 18F-FDG PET/CT in small AAA. The results suggest 
the degree of small AAA metabolism may not be reflected in the blood levels of serum 
biomarkers.  
Prospective event-driven studies combining potential biomarkers and 18F-FDG PET/CT 
in small AAA are needed to establish the role of these biomarkers in AAA risk-
stratification and future clinical practice. 
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The role of 18F-FDG PET/CT as surrogate marker of vascular inflammation is well 
established107, 209, 329, 395 and increased levels of circulating biomarkers compared to 
control subjects have been reported329, 391, 396-399. Our study confirmed higher circulating 
levels of MMP-9 and MMP-2 compared to healthy control subjects, a finding 
previously observed by Hovsepian and colleagues391. This finding affirms the role of 
MMP-9 and MMP-2 as potential biomarkers of connective tissue metabolism in patients 
with AAA. In a large prospective cohort study assessing CRP in patients with small 
aneurysms, followed up for a median of 4y, baseline CRP levels were higher in larger 
aneurysms, but CRP was not associated with expansion rate 399. Similarly, our study 
showed increased levels of hsCRP in the AAA group, albeit of only borderline 
statistical significance. This affirms the non-specific characteristics of CRP found in 
other studies399, 400. It may well be that higher levels of circulating CRP are symptom-
driven, as suggested by Domanovits396. Although reports of serum hsCRP associated 
with aneurysmal size exist, thereby underscoring the inflammatory nature of AAA 
disease401, 402, we have found no such relationship (p=0.278). Furthermore, it is unclear 
in our study why no significant difference was observed between circulating levels of 
hsIFN-γ in subjects and controls, whereas Juvonen et al392 have reported such a 
difference; it is possible that small participant numbers may explain our results.  
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The specific regulatory traits of components of the inflammatory cascades and of 
proteases that cause aneurysmal progression remain largely unresolved. In particular the 
role of Th1 cytokine IFN-γ in AAA disease continues to be debated. In animal studies, 
Th1 cytokines together with leukocyte recruitment typically characterize early 
atherogenesis403, 404 and IFN-γ-depleted mice demonstrate markedly augmented 
inflammatory responses, suggesting Th1 cytokines might even protect against aneurysm 
development405. Other researchers have found that CD4-deficient mice do not develop 
experimental aneurysms, unless IFN-γ is administered131. However, this cytokine, 
depending on the experimental environment, may either induce or inhibit AAA 
formation. IFN-γ inhibits MMP-9 production406, 407 in murine and human macrophages 
and collagen production by VSMCs408. Furthermore, reports suggest a relationship 
between levels of circulating metalloproteinases (MMP-1, -3, and  -9) and vessel wall 
18F-FDG uptake in patients with vascular disease216, 319. In contrast, our study revealed 
no association between 18F-FDG uptake in small aneurysm walls and circulating 
markers of vascular inflammation, thus suggesting the degree of small AAA wall 
metabolic activity may not be reflected in the blood levels of biomarkers.  Altough it is 
believed that macrophage metabolic activity is central to inflammatory cascades in 
AAA, our finding confirms reports that these inflammatory cascades are complex and 
poorly understood304. In this cohort, a low median 18F-FDG TBRmax (median uptake 
1.4+0.3) and lack of association with circulating markers imply this association appears 
to be difficult to evaluate.  
 
This also questions the ability of the studied circulating biomarkers to reflect or detect 
vascular inflammation, and therefore their diagnostic and risk-stratification potential in 
small AAA. Golledge et al in their extensive review on potential circulating markers of 
AAA diagnosis and progression, reported that biomarker sensitivity and specificity 
appear inadequate for the use of an individual circulating marker in AAA diagnosis and 
therefore called for combined biomarker diagnostic potential to be evaluated in large 
population-based studies394. Furthermore, Li et al questioned whether all accumulations 
of 18F-FDG within the arteries are due to macrophage-mediated inflammatory activity, 
since high levels of 18F-FDG were observed in patients with both high and low risk 
cardiovascular disease409. Nevertheless, reproducibility of results when large arteries 
were studied confirms the useful application of the 18F-FDG tracer in vascular 
inflammation imaging319.  
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Our study observed a lower AAA 18F-FDG uptake in subjects with hypertension 
(p=0.040). This may be due to effective medical therapy in our study group (11 subjects 
were taking B-blockers and 4 subjects an ACE-inhibitor) at the time of the 
investigation. Both Beta-blocker and ACE-inhibitor use has been associated with a 
marked reduction in the increased circulating levels of cytokines410, 411. Similar to 
Rudd316, 410, 411 and in contrast to Tahara217, 316, 410, 411 we have found no relationship 
between statin use and 18F-FDG uptake. This is most likely due to the small sample size 
in our non-statin subgroup. 
 
Multiple risk factors for atherosclerosis and AAA development and rupture including 
age, gender, hypertension, raised lipids and smoking have been identified182, 412. It is 
reassuring in our study that subjects with risk factors for atherosclerosis (raised lipids, 
hypertension, ischaemic heart disease, ex-smokers) had significantly higher hsMMP-9, 
hsMMP-2 levels, given that the relationship between these biomarkers and AAA is well 
established327, 391, 398 Similar to previous observational work413, 414 we observed higher 
levels of hsCRP (p=0.047) in subjects who had stopped smoking. Chronic low grade 
inflammation measured as a continuous high hsCRP is thought to be a consequence of 
smoking and a marker of tissue injury, suggesting continuous inflammation (ie high 
levels of hsCRP) can persist long after smoking cessation413, 414. It is thought that 
metabolic factors (such as weight gain) contribute to such a persistent inflammatory 
state413.  
 
There are study limitations and technical considerations when interpreting our findings.  
In this study we have performed a whole vessel type texture analysis to avoid 
misleading findings on limited aneurysm area, thereby increasing the validity of our 
study findings and in keeping with recommended AAA PET/CT analysis210. The study 
population size of 24 is small but compares favourably with many initial functional 
arterial PET studies357, 358. Nonetheless, larger and more extended and perhaps 
combined studies of several vascular serum biomarkers and PET are needed.  
 
In conclusion, this chapter has presented the first investigation of the possible 
association of AAA wall metabolic activity as measured by 18F-FDG PET/CT and 
circulating serum biomarkers in small AAA. The results suggest the degree of AAA 
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wall inflammation is generally not reflected by levels of the circulating serum 
biomarkers studied. However, to demonstrate such a relationship may prove difficult 
due to the relatively low metabolic activity in the arterial walls of small AAA, and large 
participant numbers may be required to overcome inherent PET limitations.  
 
Summary of findings: 
 Cardiovascular risk factors were associated with higher serum levels of hsMMP-9 and 
hsMMP-2.  
 Patients with AAA had significantly higher levels of hsMMP-9 and hsMMP-2 (adjusted 
for age, gender, hypertension, ischaemic heart disease, raised lipids and statin use) 
compared to healthy controls.  
 No correlations were found for AAA 18F-FDG uptake and circulating levels of hsMMP-
9, hsMMP-2, hsINF-γ and hsCRP.   
 
  
  Chapter 7 Discussion  
CHAPTER 7. DISCUSSION 
 
7.1. VASCULAR METABOLISM - 18F-FDG HYBRID PET/CT UPTAKE IN AAA 
 
This project to detect increased metabolic activity with 18F-FDG-PET/CT in 
predominantly small AAAs, in patients undergoing surveillance, demonstrated that the 
majority (n=13/17) of patients (with mean AP diameter 5.4+0.8cm) had an increased 
18F-FDG uptake (SUVmax>2.5) when ROI was drawn to include hotspots in the 
aneurysm wall. From this data it is inferred that 18F-FDG PET/CT offer in vivo evidence 
that small AAA show increased glucose metabolism. We reported higher SUVmax   
values in our hybrid PET/CT camera cohort compared to a stand-alone PET camera 
study (mean AAA diameter 6.3+0.95cm) reporting only 39% high FDG uptake34. Size 
discrepancies and technology advances may in part explain our findings. It was also 
observed that aneurysm wall glucose uptake as measured by TBRmax remained 
relatively unchanged at various time points with PET imaging, even though a significant 
difference in blood-pool activity was observed between 1 and 3h. Wu et al noted in 
their dual time-point vascular 18F-FDG PET carotid study that the delayed images 
allowed for better lesion-to-background contrast during visual assessment; however, 
both the pattern and location of 18F-FDG uptake could be detected on both early and 
delayed images216. It is suggested that the resulting decay of the tracer with subsequent 
increase in image noise may be implicated in delayed arterial 18F-FDG PET imaging. 
Therefore, the possible benefits of delayed imaging are counterbalanced by the effects 
of image noise and more variable SUVmax measurements
348. Performing vascular PET at 
1h compared to 3h time-point has logistical benefits. Large multicentre PET trials to 
assess arterial inflammation and atheroma vulnerability and to monitor the effects of 
pharmacologic therapies could be made more feasible by improved workflow, and 
participation would be less onerous for patients. Since metabolic activity (to a lesser or 
greater degree) detected by 18F-FDG PET/CT is present in small AAA, we explored the 
risk-stratification potential of 18F-FDG PET in prospective aneurysm growth studies.  
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7.2. RELATIONSHIP BETWEEN 18F-FDG  AORTIC ANUERYSM UPTAKE ON PET/CT  
AND ANUERYSM GROWTH RATE 
 
This chapter takes the view that 18F-FDG PET has a potential role in risk-stratification 
of patients with aneurysms detected during screening, since aortic 18F-FDG uptake was 
inversely related to future aneurysm expansion. This finding suggests that aortic 
aneurysms with lower 18F-FDG metabolic activity seem more likely to expand. We and 
other researchers suggest aneurysm dilatation develops after initial inflammatory 
processes134, 168, 354 and calcification possibly represents a late burn-out stage of 
atherosclerosis316, 354. However, these findings need to be rationalized in light of a single 
time-point investigation and that increased 18F-FDG uptake in arteries may not persist 
with time348. Therefore, before general application of 18F-FDG PET as a marker of 
significant aneurysm expansion in clinical practice, larger scale studies should be 
performed to confirm these study findings.  Furthermore, identifying relationships when 
combining in vivo imaging techniques such as both 18F-FDG PET/CT and CT 
heterogeneity may increase our understanding of the role vascular metabolism plays in 
AAA formation and progression.  
 
7.3. INVESTIGATING AAA TEXTURE ANALYSIS AND 18F-FDG UPTAKE ON PET/CT  
AND FUTURE GROWTH RATE 
 
In this chapter a prospective longitudinal study was performed examining whether AAA 
heterogeneity using CT texture measurements were associated with future aneurysm 
expansion and also for associations between aneurysm glucose metabolism and CT 
texture. Increased coarse texture parameters (SD) were found in aneurysms that exhibit 
lower metabolic activity affirming that surface anatomical heterogeneity changes in 
AAA walls may reflect underlying inflammatory pathobiology. The medium texture 
parameters (K) correlated strongest with significant AAA expansion, suggesting that 
aneurysms with greater medium heterogeneity (K) may be more likely to exhibit greater 
AAA expansion. This part of the thesis therefore identified CT texture characteristics 
and 18F-FDG PET uptake derived from baseline PET/CT images that are associated 
with prospective AAA growth rate, thus validating the role of these modalities in 
studying AAA and providing a foundation for further larger studies. Histological PET 
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heterogeneity studies are needed to underpin structural characteristics associated with 
significant disease progression to provide possible explanations for these study findings. 
Future studies assessing the relationship between calcium burden, AAA wall texture 
and inflammation may be useful. Furthermore, assessing the association between 18F-
FDG PET AAA uptake and circulating serum biomarkers of inflammation in patients 
with small AAA may broaden our insight into AAA pathobiology to identify 
serumbiomarkers with potential in AAA risk-stratification. 
 
7.4. SERUM BIOMARKERS AND 18F-FDG AAA UPTAKE ON PET/CT  
 
This chapter evaluated the relationship between abdominal aneurysm wall 18F-FDG 
uptake using PET/CT with recognized circulating serum biomarkers of inflammation.  
Although subjects with AAA had significantly higher levels of hsMMP-2 and -9 in our 
study and other studies391, no link between AAA 18F-FDG uptake and circulating levels 
of hsMMP-2, -9, hsINF-γ and or hsCRP were identified. Since 18F-FDG PET uptake 
reflects metabolic activity 221, 222, this finding suggests the degree of AAA wall 
inflammation may not be reflected in the blood levels of the circulating serum 
biomarkers studied. The study findings need to be rationalized against study limitations 
including small participant numbers and reproducibility challenges of ELISA assay 
results along with inherent errors in AAA SUV measurements. Furthermore, 18F-FDG is 
a non-specific PET tracer, albeit generally accumulated in greater amounts in 
macrophages in atherosclerosis.  
  Chapter 8 Conclusion and future work 
CHAPTER 8. CONCLUSION AND FUTURE WORK  
 
Screening programmes for aortic aneurysms are being introduced in North America and 
Europe. The increase in surveillance is creating demand for further risk-stratification 
whilst intensifying the need to develop strategies for managing the growth rate of small 
aneurysms. In vivo imaging of AAA using 18F-FDG hybrid PET/CT shows potential to 
identify patients at risk of disease progression. FDG PET/CT could also be considered 
as an imaging modality for possibly assessing response to non-surgical treatment and 
the need for re-intervention following EVAR.  
 
Contemporary data suggest a role for vascular PET/CT in evaluation of aortic 
dissection357 and aortitis415. This thesis aimed to increase our understanding of the role 
for clinical PET/CT in patients with small AAA. Relationships between aortic aneurysm 
wall 18F-FDG uptake and future AAA expansion were identified.  
 
Based on positive outcome of results the following recommendations are made: 
 
a. The introduction of 4-D PET and appropriate gating may help overcome recognized 
technical constraints for PET/CT, however, the ideal vascular tracer remains 
unknown289. Histological correlation studies with 68Ga-DOTATATE as vascular 
imaging tracer are needed.  
b. Further improvements in isolating the SUV measurement from the aneurysm wall might 
also improve accuracy223. We suggest further analysis using a ‘doughnut’ type ROI 
measurement of the aneurysmal wall where the ROI does not include the arterial lumen.  
c. PET/CT to investigate AAA pathobiology should be performed with intravenous 
contrast to aid more accurate identification of ILT and to facilitate further work on the 
influence of ILT in AAA pathobiology with PET/CT. 
d. CT texture analysis with particular emphasis on medium and coarse texture parameters 
could be further explored in AAA risk stratification. 
e. Furthermore, future prospective studies could also focus on large AAA and rupture risk 
stratification with PET/CT.  
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CT Textural analysis  
 
Brief description: 
The CTTA technique comprised an initial band-pass image filtration using a Laplacian 
of Gaussian (LoG) filter (Figure A1) to produce a series of derived images of the AAA, 
displaying features at different anatomical scales from fine to coarse texture (Figures A1 
and A2 and Table A1). AAA heterogeneity within each filtered image was quantified 
using histogram-based parameters, including standard deviation (SD) (degree of 
variation from the mean pixel value or scale of the distribution) and kurtosis (K) 
(pointedness of the distribution may reflect structures such as vessels). SD and K then 
describe the gray-level variation and pointiness respectively of the histograms 
representing structures within the AAA. 
 
Technical description: 
CTTA comprised of two main stages, image filtration and quantification of texture.  
Image filtration  
A LoG band-pass filter was chosen, and modulated to highlight different spatial scales 
between fine texture (filter value = 1.0) and coarse texture (filter value = 2.5). This scale 
can be considered as the width at which structures in the image wil l be highlighted and 
enhanced, while structures less than this width will become blurred. 
The two-dimensional (2D) Gaussian distribution G is given by  
  2
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          Equation 1 
where x, y are the spatial coordinates of the image matrix and σ is the standard deviation 
of the Gaussian distribution. The 2D Gaussian distribution effectively blurs the image, 
wiping out all structures at scales much smaller than the sigma of the Gaussian. This 
distribution has the desirable characteristics of being smooth and localized in both the 
spatial and frequency domains, and is therefore less likely to introduce any changes to 
the original image. Thus, the Gaussian distribution corresponding to a particular σ value 
allows the highlighting in CT images of texture features of a particular scale. We have 
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used this filtration technique to filter out textural features of varying scale, from; fine to 
medium to coarse.  
The reason for using the Laplacian (∇2) is that it is the lowest-order orientation-
independent (isotropic) differential operator and inherently has less computational 
burden and can be used to detect intensity changes in an image that correspond to the 
zero crossings of the filter. ∇2G is the LoG filter, a circularly symmetric, Mexican-hat-
shaped filter (see Figure A1 for spatial and frequency domain representations of the 
filter) whose distribution in the 2D spatial domain is given by  
       Equation 2 
 
From the mathematical expression of this circularly symmetric filter at different σ 
values, the number of pixels representing the width between the diametrically opposite 
zero-crossing points in this filter can be calculated. The width of the filter at different σ 
values is obtained by evaluating the LoG spatial distribution along the x and y 
directions. The lower the σ value, the smaller is the width of the filter in the spatial 
domain and the larger is the band-pass region of the filter in the frequency domain, 
highlighting fine details or features in the filtered image in the spatial domain. Similarly 
in the spatial domain, a higher σ value allows coarse features to be highlighted in the 
filtered image.  
 
Filtration can be done in the spatial or frequency domain. In the spatial domain, the 
filter mask is convolved with the image, which involves intensive computation. It is 
more efficient to use the filter in the frequency domain, as convolution of the filter mask 
and the image in the spatial domain is equivalent to multiplication of the Fourier 
transforms of the filter mask and image in the frequency domain. The inverse Fourier 
transform of the filtered spectrum gives the resultant filtered image in the spatial 
domain. Also, the accuracy of this filtering operation is improved when used in the 
frequency domain, as the quantization errors arising from the convolution of the filter, 
especially for small σ values in the spatial domain, would distort the image. In our 
study, the filter was applied in the frequency domain.  
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Quantification of texture 
A region of interest (ROI) was placed to include the aneurysm wall and content as well 
as to include only the luminal content on each individual axial slice comprising the 
whole vessel AAA. The ROI was further refined by the exclusion of areas of air with a 
thresholding procedure that removed from analysis any pixels with attenuation values 
below -50 HU. Median ROI size (from the whole vessel AAA) was 20919 pixels 
(range, 4084-123572 pixels). The ROIs for texture analysis were stored as a binary 
mask and assigned to the corresponding individual patient lesion. This ensured that the 
same patient-specific ROI was used for the texture analyses of different σ values. The 
resulting images underwent 2D band-pass filtering with the LoG filter using each of the 
following filter values: (fine, filter width: 2mm radius); (medium, filter width: 3-5mm 
radius); (coarse, filter width: 6mm radius) (Table A1). Heterogeneity within this ROI 
was quantified with image filtration. The histogram of AAA pixel values with image 
filtration was characterized by SD (degree of variation from the mean pixel value or 
scale of the distribution) and K (pointedness of the distribution may reflect structures 
such as vessels) using the equations below:     
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where R  is the ROI within the image ),( yxa , n  is the total number of pixels in R , a  
is the mean value within R .  
 
Table A1 Filter values and the corresponding widths of the filter in mm 
Filter value Filter width (radius)  in mm 
Fine 2 
Medium 3-5 
Coarse 6 
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     SPATIAL DOMAIN                   FREQUENCY DOMAIN 
    
 (Image Format)             (Image Format)  
Figure A1 The 2-D forms of the LoG filter in the spatial and frequency domain 
at extract medium texture 
 
        
                               (Plot)                                             (Plot) 
 
Figure A2 The 2-D forms of the LoG filter in the spatial and frequency 
domain at filter value of 2.0 (extract medium texture) 
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